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LIGAND-INDUCED CONFORMATIONS OF
EXTRACELLULAR LOOP 2 OF AT1R

HAMIYET UNAL

ABSTRACT

Angiotensin II type 1 receptor (AT1R) is a G-protein coupled receptor (GPCR)
and an important regulator of blood pressure. It is a target for drug development, because
abnormalities in its function are linked to hypertension, cardiac hypertrophy and heart
failure. AT1R is composed of seven transmembrane helices connected by three
extracellular loops and three intracellular loops. The extracellular loop 2 (ECL2) of
AT1R directly interacts with the ligands. This loop is targeted by autoantibodies that
activate AT1R in several pathologies such as preeclampsia, malignant hypertension and
vascular allograft rejection. Therefore, we proposed that the conformation of ECL2 in
AT1R is differentially regulated upon binding to agonists and antagonists.

We determined the conformation of the ECL2 of AT1R by reporter-cysteine
accessibility mapping in different receptor states (i.e., empty, agonist-bound and
antagonist-bound). We introduced cysteines at each position of ECL2 of a receptor
surrogate lacking all non-essential cysteines and measured reaction of these with a
cysteine-reactive biotin probe. The ability of biotinylated mutant receptors to react with a
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streptavidin-HRP-conjugated antibody was used as the basis for examining differences in
accessibility.

Two segments of ECL2 were accessible in the empty receptor, indicating an open
conformation of ECL2. These segments were inaccessible in the ligand-bound states of
the receptor. Using the accessibility constraint, we performed molecular dynamics
simulation to predict ECL2 conformation in different states of the receptor. Analysis
suggested that a ‘lid’ conformation of ECL2 was induced upon binding to both agonists
and antagonists, but exposing different accessible segments delimited by a highly
conserved disulfide bond between ECL2 and TMIII. We propose that the ligand-induced
ECL2-lid is coupled to movements of transmembrane helices through the conserved
disulfide bond to achieve the transition to the active state of the receptor.

Our study reveals the ability of ECL2 to interact with diffusible ligands and adopt
a ligand-specific ‘lid’ conformation. Distinct conformations induced by the agonist and
the antagonist around the conserved disulfide bond suggest an important role for the
disulfide bond in producing different functional states of the receptor. Dynamics of ECL2
may regulate the fundamental process of receptor activation and pathophysiological
processes involving GPCRs.
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CHAPTER I
INTRODUCTION

1.1 G-Protein Coupled Receptors (GPCRs)
1.1.1

General Features of GPCRs
G-protein-coupled receptors (GPCRs) are seven-transmembrane helix proteins

that are coupled to guanine nucleotide-binding proteins (G-proteins) upon activation by a
specific ligand. GPCRs are the largest family of cell surface receptors, having a major
role in signal transduction. They are ubiquitously expressed in eukaryotes, from yeast to
human, and represent 2% of the genes in the human genome with approximately 1000
members (Takeda et al, 2003). GPCRs convey extracellular signal across the cell
membrane as a response to a diverse array of ligands including hormones, ions,
neurotransmitters, proteins/peptides, fatty acids, small molecules and physical stimuli
such as light, smell, taste and mechanical stretch (Lagerstrom and Schioth, 2008,
Rosenbaum et al, 2009). GPCRs constitute a significant field of research due to their
relevance to membrane biophysics, cell signaling, pharmacology, physiology,
pathophysiology and drug discovery. 50% of all current human therapeutics is
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targeted to GPCRs, which only constitutes a small fraction of known GPCRs. Therefore,
there is an extensive search for new drugs that target GPCRs with high efficacy and
specificity. Due to the relevance of GPCRs to drug discovery, understanding the roles of
GPCR signaling in physiology and pathophysiology and delineating the structurefunction relationships of GPCRs have been a major focus of studies in receptor biology.

GPCRs are transmembrane proteins with a common architecture (Fig 1.1 A)
characterized by seven-transmembrane (TM) helices, connected by extracellular loops
(ECL) and intracellular loops (ICL) (Lagerstrom and Schioth, 2008, Rosenbaum et al,
2009). The N-terminal tail faces the extracellular region while, the C-terminal region is
intracellular. When the GPCRs fold to a three-dimensional structure within the
membrane, the TM helices forms an aqueous channel open to the extracellular space.
This channel is filled with water molecules forming a ligand binding pocket, 20-30 Å
deep in the TM domain (Fig. 1.1 B&C). Ligands bind to the receptor on the extracellular
side. The rigid body movements of TM helices, with a length of 25-30 residues, transmits
the signal to the intracellular loops which bind and activate the heterotrimeric G-protein.
The intracellular loops, particularly the second and third loops, are the critical sites for Gprotein interaction. (Bockaert and Pin, 1999) The G-protein consists of an α-subunit,
responsible for GTP/GDP binding and GTP hydrolysis, and a complex formed by β- and
γ-subunits. The intracellular loops determine the specificity of a GPCR for a particular
subtype of α-subunit of G-proteins such as Gαs, Gαi and Gαq. The intracellular loops of
different GPCRs specifically interact with certain G-protein subtypes but, they also have
a low affinity for other subtypes. Upon activation, the GDP of the G-protein is exchanged

2

Figure 1.1. General configuration of GPCRs. A) Depiction of the secondary structure
of a GPCR. B) Depiction of the three dimensional structure of a GPCR. C) Depiction of
the ligand binding pocket of a typical family A GPCR. (from Ji et al, 1998)
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with GTP which results in dissociation of the α and βγ subunits of the heterotrimeric
protein. Dissociated Gα and Gβγ subunits further activates intracellular downstream
effectors such as adenylyl cyclases and phospholipases which in turn affect the levels of
second messengers such as cAMP and calcium. In addition to the classical secondmessenger mediated signaling pathways activated through G-protein coupling, recent
studies have discovered a number of alternative signaling mechanisms that are related to
diverse biological functions of these receptors (Pierce et al, 2002). GPCRs can also signal
in a G-protein-independent manner, leading to activation of mitogen-activated protein
kinase (MAPK) pathways (Miura et al, 2004). The cytoplasmic tail of GPCRs is target
for agonist-induced posttranslational modifications such as phosphorylation and
palmitoylation. The C-terminal tail of activated GPCRs is phosphorylated by G-proteincoupled receptor kinases (GRKs). The phosphorylated C-terminal tail of a GPCR recruits
intracellular proteins such as β-arrestin and leads to internalization followed by recycling
or lysozomal degradation (Tan et al, 2004). Palmitoylation of some GPCRs at the
cysteine residues, found in the C-terminal tail, creates a fourth loop which may regulate
the phosphorylation and internalization (Resh, 2006).

The assembly of GPCRs into dimers and oligomers adds an additional level of
complexity to the mechanisms underlying the functioning of GPCRs. The ability of
GPCRs to interact with various intracellular proteins that activate various signaling
pathways provide a mechanism for physiological regulation of biological activity.
Mechanisms for GPCR regulation occur during their biosynthesis by gene transcription,
translation, and posttranslational processing or, during trafficking to the cell membrane.
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Once the receptor is on the cell membrane, the regulatory mechanisms involve the
process of GPCR desensitization and internalization, receptor recycling and lysosomal
degradation.

1.1.2

Classification and Evolution of GPCRs
The gene repertoire of GPCRs extends from yeast to complex eukaryotic

organisms including the nematodes, insects, plants, and mammals, indicating their
evolutionary success (Fredriksson et al, 2003). GPCRs are not found in prokaryotes.
Bacteriorhodopsin is a light-sensing seven transmembrane protein found in bacteria,
which might have a common origin with GPCRs in eukaryotes. It is a proton pump
involved in producing energy. However it is not a GPCR, does not couple to G-proteins,
and does not have significant sequence homology to GPCRs (Okada and Palczewski,
2001).

Phylogenetic analysis classifies GPCRs into five families based on their sequence
and structural similarities (Fredriksson et al, 2005). These families are Rhodopsin,
Secretin, Adhesion, Frizzled/Taste2, and Glutamate families, known as the GRAFS
classification system (Fig. 1.2). Surprisingly, there is minor sequence homology between
different GPCRs families. In addition to lack of amino acid sequence conservation, there
is variation in the length and function of their N-terminal and C-terminal domains and
extracellular and intracellular loops. These types of variations give specific structural
properties to different GPCRs. However, the sequence comparison within a particular
receptor family shows some degree of sequence similarity. Sequence analysis within a
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Figure 1.2. Evolutionary tree of GPCRs in different species. Adapted from
Fredriksson et al, 2005.
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particular family reveals conservation of amino acids with similar residue type, rather
than the sequence identity. Compared to N-terminal (7–595 amino acids) and C-terminal
regions (12–359 amino acids), the size and sequence of TM domains (20–27 amino acids)
are highly conserved, as well as the size of the loops (5–230 amino acids).

Among GPCR families, the rhodopsin family is the largest and the most diverse,
representing approximately 60% of the GPCR repertoire. The rhodopsin family is further
divided into subgroups, based on ligand similarity, including opsins (rhodopsin etc.)
amine receptors (muscarinic receptors, adrenoreceptors, dopamine receptor, serotonin
receptor), peptide receptors (angiotensin receptor, bradykinin receptor, chemokine
receptor, opioid receptor, etc.), glycoprotein binding receptors (follicle stimulating
hormone receptor, thyrotropin receptor, etc.), olfactory receptors, and nucleotide like
receptors (Fredriksson et al., 2003). The characteristic feature of the rhodopsin family is
the presence of conserved amino acid sequences, such as the NPxxY motif at the end of
TMVII, the DRY motif at the end of TMIII, and the conserved N residue in TMI. The
presence of such motifs suggests common structural features and activation mechanisms.
Most of the ligands for rhodopsin family GPCRs bind within a cavity formed by the TM
helices (Baldwin, 1994). However, the ligand-binding domain in the glycoprotein binding
receptor family is in the N-terminus.

The receptors in other GPCR families, particularly in the adhesion family, have
long N-terminal regions. The long N-terminus (200-280 amino acids) of adhesion family
receptors are suggested to interact with other membrane bound proteins which provides
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cell-to-cell adhesion in a ligand independent manner. They have conserved sequence
motifs within the N-terminus, such as epidermal growth factor (EGF)-like repeats,
mucin-like regions, and conserved cysteine-rich motifs (Fredriksson et al, 2005).

The secretin family of GPCRs also contains the ligand binding domains in their
N-terminal region. These binding domains interact with large peptides with paracrine
actions that share sequence similarity. The N-terminus (60-80 amino acids) contains
conserved cysteine bridges that are likely to participate in ligand binding. Some examples
of secretin family GPCRs are the calcitonin receptor, glucagon receptor and parathyroid
hormone receptor (Fredriksson et al, 2005).

The glutamate family GPCRs also has a long N-terminal region (280 to 580
amino acids) with the ligand binding domain that interacts with small molecules such as
glutamate, gamma-aminobutyric acid (GABA), calcium ions, and taste molecules. The Nterminus forms a “Venus fly trap” structure with a cavity in which glutamate binds
(Fredriksson et al, 2005).

The frizzled family of GPCRs signals through glycoproteins called Wnt and
mediates cell fate, proliferation, and polarity during development. The N-terminus (200
amino acids) of the frizzled family of receptors contains conserved cysteines and
participates in Wnt binding (Fredriksson et al, 2005).
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1.1.3

Structural Features of GPCRs
The structural knowledge of GPCRs has been obtained by the three dimensional

crystal structure of a prototypical GPCR, bovine rhodopsin covalently bound to the
inverse agonist 11-cis retinal (Palczewski et al, 2000), sequence alignment and molecular
models based on the rhodopsin structure, and site-directed mutagenesis studies.
Complementary biophysical approaches have been performed to understand the dynamic
features of GPCRs that enable transition of signals triggered by ligand binding to
intracellular proteins. (Hamm, 2001) These approaches include site-directed spin labeling
(Yang et al, 1996, Farrens et al, 1996, Altenbach et al, 1996) and electron paramagnetic
resonance (EPR), fluorescence spectroscopy (Loewen et al, 2001), substituted cysteine
accessibility mapping, and nuclear magnetic resonance (NMR) spectroscopy (Ahuja et al,
2009, Bokoch et al, 2010). All of these studies provided insight into the general
configuration of GPCRs, positioning of the TM domains, and residues participating in
ligand binding and interaction with intracellular signaling proteins. These studies
improved our understanding of molecular mechanism of GPCR activation and signaling.

These studies have been followed by the high resolution inactive structures of
several other GPCRs, including the human β2 adrenergic receptor bound to the inverse
agonists carazolol and timolol (Cherezov et al, 2007, Rasmussen et al, 2007), the avian β1
adrenergic receptor bound to the antagonist cyanopindolol (Warne et al, 2008), and the
human A2A-adenosine receptor bound to the antagonist ZM241385 (Jaakola et al, 2008).
Furthermore, the structures of the active, unliganded opsin (Park et al, 2008) and opsin
bound to the C-terminal sequence of the G protein, transducin (Scheerer et al, 2008) have
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been solved and provided information about the conformational changes associated with
active state of rhodopsin. There are both similarities and differences among the four
known inactive structures of GPCRs. The extracellular domains, including the ends of the
TM helices and the extracellular loops, show the greatest difference which may allow the
recognition of a wide spectrum of ligands. (Rosenbaum et al, 2009)

The ligand binding domains of these rhodopsin family GPCRs share remarkable
similarity. However, between GPCR families, the ligand binding domains show diversity.
The ligand binding pocket for small molecular weight ligands is within the hydrophobic
core formed by the TM helices whereas the ligand binding sites for larger peptides
include the N terminus and the extracellular loops, as well (Perez and Karnik, 2005).

The conserved structural features of GPCRs suggest a common molecular
mechanism for ligand-induced activation among different families of GPCRs (Gether,
2000). The previous studies of rhodopsin, a prototypical GPCR, provide useful
knowledge on ligand-receptor interactions of TM and intracellular domains. However,
the structure-function relationships of extracellular domains have not been well
understood. Although the interactions with TM helices are recognized as the major factor
for activation of GPCRs, accumulating evidence has revealed a new and unanticipated
role for the extracellular loops (ECLs) in the functioning of GPCRs (Karnik et al, 2003).
Compared to the variable structure of N-terminus, the lengths of all other ECLs are
highly conserved among GPCRs, which implies that a conserved function is mediated by
the extracellular domain. The significance of the extracellular domains for ligand binding
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and receptor activation has been shown for the majority of GPCRs from different
families. For the rhodopsin family GPCRs, the ligand binding site is found deep within
the seven transmembrane bundle. However, small peptide ligands make contact with the
ECLs while entering the TM core. In the secretin family of GPCRs which are
characterized by longer N-terminal domains, ECLs contribute to receptor activation
altough the ligand binds to the N-terminal domain. The interaction of ligand with ECLs is
crucial for the TM domains to activate the glutamate family of receptors. The ligandinduced activation of the other two GPCR families, adhesion and frizzled receptors has
been shown to be impaired by the mutations in ECLs. These observations suggest a
conserved role for the extracellular domains throughout the GPCR superfamily (Karnik et
al, 2003).

In addition, the extracellular loop 2 (ECL2) is characterized by a highly conserved
disulfide bond linking the loop to the TMIII in more than 90% of GPCRs. Disruption of
this disulfide linkage directly affects receptor folding and function in most GPCRs,
indicating an important role for the disulfide bond and ECL2 in receptor structurefunction relationships (Karnik et al, 2003). The ECL2 attracted additional interest upon
the elucidation of the high-resolution crystal structure of bovine rhodopsin, the first
structure of a mammalian GPCR. In this structure, the loop makes extensive contacts
with the other extracellular domains and adopts an anti-parallel β-hairpin structure that
projects into the TM core, covering the retinal binding site (Palczewski et al, 2000). On
the other hand, unlike the buried β-hairpin structure in rhodopsin, the ECL2 in the
recently solved structures of β2 and β1 adrenergic receptors has an extra helix and an
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intraloop disulfide bond in addition to the conserved disulfide bond between ECL2 and
TMIII (Cherezov et al, 2007, Rasmussen et al, 2007, Warne et al, 2008). Despite this
conformational difference, different GPCR structures predict that ECL2 is a part of the
ligand binding pocket and has a vital role in receptor function.

1.1.4

Activation of GPCRs
Transmembrane signal transduction during the activation of GPCRs adheres to a

common molecular mechanism (Karnik et al, 2003). Binding of activating ligands to a
GPCR induces rigid-body movements of TM helices which facilitate G-protein
activation, leading to cytoplasmic signal transduction. Elucidating the nature of the
conformational changes in GPCRs that are induced by different types of ligands is critical
to understand the molecular mechanism of GPCR signaling. GPCRs show some level of
basal activity in the absence of an agonist and activate the G-protein in an agonist
independent manner. This basal activity can be modulated by different types of ligands.
Agonists are ligands that fully activate the receptor, whereas partial agonists induce
submaximal activation of the G-protein, even at saturating concentrations. Inverse
agonists reduce the basal activity and antagonists compete with the other ligands without
affecting on basal activity (Kiya et al, 2010).

Different models have been proposed to explain GPCR activation upon agonist
binding (Perez & Karnik, 2005). The “bimodal switch model” simply proposes that the
receptor exists in equilibrium between the inactive state and the active state. The level of
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basal receptor activity is determined by the equilibrium between these two states in the
absence of agonists. The binding of ligand changes the equilibrium between active and
inactive states.

A more complex model suggests that constraining interactions keep the receptor
in an inactive conformation. Upon activation by agonists or activating mutations, these
interactions are released, exposing the key residues for the G-protein interaction. The
unbound receptor can assume several intermediate conformational states with different
affinities for the G-protein. Each conformation can selectively interact with a ligand,
leading to a specific intracellular signaling outcome. The inverse agonist stabilizes the
inactive state by increasing the number of constraining interactions, whereas the agonist
stabilizes the active state by releasing such interactions. Partial agonists may stabilize an
intermediate state that has lower affinity for the G-protein. G-proteins may also interact
with the empty receptor and stabilize the receptor in a different intermediate state that
increases the affinity for agonist. The modulation of basal activity of GPCRs by different
types of ligands indicates the dynamic nature and inherent flexibility of GPCRs and the
existence of multiple conformational states in the absence of ligands (Perez & Karnik,
2005). Evidence suggests that during agonist binding and activation, the receptor
undergoes a series of intermediate conformations through interactions formed between
the receptor and the agonist, disruption of constraining intramolecular interactions that
stabilize the basal state of the receptor and rearrangement of a new set of intramolecular
interactions (Kobilka and Deupi, 2007, Ahuja and Smith, 2009). The flexibility of
GPCRs is essential for their physiological functions (Kobilka and Deupi, 2007). A better
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understanding of the dynamic nature of GPCRs might facilitate structure based drug
discovery.

The fundamental question of the mechanism of GPCR activation is, what are the
conformational changes induced by agonist which are then propagated to the cytoplasmic
domain that couples to the G-protein. The recent crystal structures of active states of
opsin (Park et al, 2008, Scheerer et al, 2008) and solid-state nuclear magnetic resonance
(NMR) studies provide insight into the transmembrane helix rearrangements upon agonist
binding. Ahuja et al (2009) has shown that conformational changes upon light activation
of rhodopsin includes movement of TM helices that disrupts a hydrogen-bond network
between ECL2 and the extracellular ends of TMIV, TMV and TMVI, displacing the
ECL2 during rhodopsin activation. Using NMR spectroscopy, Bokoch et al (2010)
reported that ECL2 of the β2-adrenergic receptor is in distinct conformations depending
on the type of the ligand bound to the receptor, and identified ECL2 as a direct reporter of
the receptor’s active state.

1.1.5

GPCRs and Disease
Coordination of signaling networks activated by GPCRs ensures proper

functioning of biological systems. GPCRs have significant roles in the regulation of
physiology. GPCR related defects have been shown to cause a wide range of genetic and
somatic diseases including cardiovascular diseases and cancer (Paul et al, 2007).
Mutations observed in GPCRs may cause deficiency in cell surface expression or ligand
binding, generation of abnormal signals, constitutive activation, or uncontrolled
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desensitization and internalization, all of which may lead to disease conditions. These
mutations have been identified particularly in GPCRs that mediate the actions of sensory
signals, hormones and neurotransmitters. Some examples are rhodopsin, gonadotrophin
receptor, calcium sensing receptor, angiotensin receptors and vasopressin receptor. (Table
I.I) Some beneficial mutations of GPCRs have also been reported, such as a mutation in a
chemokine

(CCR5)

receptor.

CCR5

receptor

is

a

co-receptor

for

human

immunodeficiency virus (HIV). A mutation in this receptor prevents the interaction of
HIV with target cells, preventing HIV infection. (Galvani and Novembre, 2005) Diseases
related to mutations in GPCRs are not common and observed in less than 1% of the
human population. Some genetic variations in GPCRs, including single nucleotide
polymorphisms (SNP), are also identified as contributors to diseases (Paul et al, 2007).
Disease-related polymorphisms have been identified in angiotensin II type 1 and type 2
receptors (Baudin, 2005) and chemokine receptor (Insel et al, 2007). Many other diseases
are caused by malfunctioning of GPCR signaling in cellular systems. Systemic disorders
such as cardiovascular diseases (hypertension, heart failure), metabolic diseases
(diabetes, obesity, kidney damage) respiratory diseases (asthma), and degenerative
diseases (Parkinson’s disease) are related to loss of regulation of GPCR signaling. As a
therapeutic approach, agonists and antagonists of GPCR have been proved useful for
treatment of these diseases. Development of more specific and effective drugs is the
major goal in the field of GPCR research.
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Table I.I Examples of disease causing mutations in GPCRs. Adapted from Paul et al,
2007.

Receptor/Gene name

Mutation

Calcium-Sensing/CaSR

Multiple (e.g. Arg185Gln)

Disease
Autosomal Dominant Hypocalcemia,
Sporadic and Familial Hypoparathyroidism

Multiple (e.g. Ser338X)

WHIM syndrome

Multiple (e.g. Trp276Cys)

Hirschsprung’s disease

Multiple (e.g. Ala189Val)

Female infertility

Phe110Ser, Cys126Trp

Juvenile periodontitis

Multiple (e.g. Arg417Gln)

Familial exudative vitreoretinopathy

Multiple (e.g. Arg262Gln)

Hypogonadotropic hypogonadism

Multiple (e.g. Cys223Arg)

Hypogonadotropic hypogonadism

Multiple (e.g. Cys223Arg)

Bilateral frontoparietal polymicrogyria

(constitutively active)

Kaposi’s sarcoma

Relaxin family peptide
receptor 2/LGR8

Multiple (e.g. Thr222Pro)

Cryptorchidism

MASS1

Multiple (e.g. Ser2652X))

Usher syndrome
Febrile seizures

Multiple (e.g. Pro78Leu)

Dominant and recessive obesity

Multiple (e.g. Pro23His)

Retinitis pigmentosa

Multiple (e.g. Arg113Trp)

Nephrogenic diabetes insipidus

Gly578Asp

Familial male precocious puberty

Multiple (e.g. Arg324Gln)

X-linked mental retardation

CXCR4
Endothelin receptor
B/EDNRB
Follicle-stimulating
hormone/FSHR
N-formyl-peptide
receptor/FPR1
Frizzled/FZD4
Gonadotropin-releasing
hormone/GNRHR
GPR54/GPR54
GPR56/GPR56
vGPCR/KSHV-GPCR

Melanocortin/MC4R
Rhodopsin/RHO
Vasopressin receptor/AVPR2
Luteinizing hormone
receptor/LHR
Angiotensin II type 2
receptor/ AT2R
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1.1.6

Drug Discovery
The molecular models of GPCRs have been extensively used for in silico

screening and identification of novel small-molecule ligands (Karnik et al, 2003). The
availability of crystal structures of several GPCRs has enabled more precise screening for
those GPCRs.

Three different types of therapeutic agents targeting GPCRs, including orphan
GPCRs, have been identified by virtual screening of synthetic chemical libraries and
natural compounds. First, novel agonists that activate GPCRs have been particularly
useful for orphan GPCRs whose endogenous ligands are not known. Second, antagonists
are also very useful for elucidating the cellular roles of orphan GPCRs. They are highly
important for treatment of diseases related to GPCR overactivity for which we do not
have an effective therapy. Third, inverse agonists can target the constitutively active
mutants of GPCRs which can not be effectively inhibited by antagonists. The inverse
agonists are also useful for characterization of orphan GPCRs. There are a few examples
of other types of novel therapeutic agents that specifically target heterodimers of some
GPCRs. An example is a drug specifically designed against the µ-opioid/δ-opioid
receptor heterodimer (Daniels et al, 2005).

1.2 Angiotensin II Type 1 Receptor (AT1R)
1.2.1

Renin Angiotensin System
The renin angiotensin system (RAS) plays a critical role in maintaining the salt-

water balance as well as blood pressure. The RAS is activated in response to decreased
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plasma sodium and fluid volume, resulting in stimulation of the renin enzyme secretion
from juxtaglomerular cells of the kidneys (Fig. 1.3). The enzyme renin cleaves
circulating angiotensinogen to angiotensin I (Ang I), which is a decapeptide representing
the N-terminus of angiotensinogen. The C-terminal dipeptide of Ang I is hydrolyzed by a
carboxypeptidase, angiotensin converting enzyme (ACE), to produce Ang II. It is an
extremely potent vasoconstrictor hormone and acts on the adrenal glands to stimulate the
release of aldosterone, increasing blood pressure. Ang II interacts with two types of Gprotein coupled receptors to elicit a cellular response; angiotensin II type 1 (AT1R) and
angiotensin II type 2 (AT2R) receptors (Gasparo et al, 2000).

The major cardiovascular effects associated with Ang II are mediated through AT1R,
such as vasoconstriction, aldosterone and vasopressin secretion, and activation of
sympathetic nervous system (Dinh et al, 2001). The physiological effects of AT2R
remain to be discovered. AT2R is known to antagonize the AT1R effects and possibly
plays role in several AT1R-independent biological processes such as apoptosis and
cellular differentiation (Table I.II). In contrast to global expression of AT1R in many
tissues, AT2R is only expressed during fetal development. The vital functions of AT1R
have also been indicated by the severe effect of complete ablation of AGT1R gene.
However, AGTR2 gene depletion does not show defective phenotypes, except for a slight
increase in the blood pressure (Oliverio et al, 1998). Moreover, AT1R mutations are very
rare in populations, whereas AT2R mutations can be tolerated. Over activity of RAS is
related to many diseases including hypertension, heart-failure, diabetes, renal and
inflammatory diseases (Teerlink, 1996). The hypertrophic effects of RAS are elicited by
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Figure 1.3. The Renin-Angiotensin system (RAS). Decreased blood pressure stimulates
renin secretion from kidneys. Renin cleaves angiotensinogen into Ang I, which is in turn
cleaved by ACE to produce the octapeptide Ang II. Ang II is the major active peptide of
RAS that regulates blood pressure through vasoconstriction and stimulation of
aldosterone and vasopressin (ADH) release. Ang II may also give rise to pathological
conditions such as cardiac and vascular hypertrophy and end-organ damage.
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Table I.II. Differential effects of AT1R and AT2R stimulation by Ang II. Adapted
from Siverstein and Ram, 2005

AT1R

AT2R

Increased vasoconstriction

Regulation of fetal tissue development

Increased aldosterone synthesis & secretion

Regulation of cell growth and proliferation

Increased tubular sodium reabsorption

Regulation of extracellular matrix composition

Increased vasopressin secretion

Regulation of cell differentiation

Increased cardiac hypertrophy

Regulation of apoptosis

Increased cardiac contractility

Regulation of left ventricular remodeling

Increased vascular smooth muscle proliferation

Increased neuronal regeneration

Increased noradrenergic activity

Vasodilation

Cell growth and proliferation

Antiproliferation
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the binding of Ang II to the AT1R. Genetic manipulations of the mouse AGTR1 gene
significantly alter blood pressure as well as cardiac and renal functions (Paradis et al,
2000). Drugs targeting AT1R can effectively lower blood pressure, whereas drugs
targeting AT2R do not have an effect on RAS induced pathologies.

1.2.2

Significance of AT1R
The AT1R is a 359 amino acid peptide hormone GPCR which belongs to the

rhodopsin family. It is expressed in liver, kidney, aorta, lung, uterus, ovary, spleen, heart,
adrenal, and vascular smooth muscles. Upon Ang II binding, AT1R productively couples
to the G-protein, Gαq/11, which leads to the activation of phospholipase C (PLC),
producing inositol-1, 4, 5-triphosphate (IP3) and Diacylglycerol (DAG). Calcium
mobilization results in smooth muscle cell contraction, which is associated with increased
blood pressure (Fig. 1.4). The intracellular downstream signaling involves the
phosphorylation of extracellular signal regulated kinases (ERK1/2) in cells (Fig. 1.4). In
addition, the AT1R activates tyrosine kinases such as Janus Kinase (JAK) and epidermal
growth factor receptor (EGFR) (Gasparo et al, 2000, Miura et al, 2004).

AT1R is an important target for drug development, because abnormal AT1R function
causes hypertension, water-electrolyte imbalance, cardiac hypertrophy and heart failure,
which are the main causes of death in the Western world. The importance of AT1R
activation has been demonstrated in all of these diseases. ACE inhibitors and AT1R
antagonists, also known as AT1R blockers (ARBs), are used effectively as therapeutic
agents to lower blood pressure and to prevent cardiac and vascular hypertrophy
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Figure 1.4. The major AT1R signal transduction pathway. Ang II binding activates
the Gq coupled signaling pathway leading to activation of PLC, which results in calcium
moblilization and activation of MAPK.
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(Siverstein and Ram, 2005, Doulton et al, 2005). ACE inhibitors compete with ACE to
reduce Ang II production, whereas, ARBs compete with Ang II for binding to AT1R. The
ARBs are well tolerated with fewer side effects than ACE inhibitors. ARBs completely
block actions of Ang II on the AT1R, irrespective of whether Ang II is generated
systemically or by non-ACE mediated pathways. Several ARBs available for the
treatment of RAS associated disorders are losartan, for treatment of hypertension and
hypertrophy, irbesartan, for treatment of diabetic nephropathy, and valsartan, for
treatment of heart failure in people who cannot tolerate ACE inhibitors. Understanding
the activation mechanism of AT1R is very important for development of more effective
therapeutic agents.

1.2.3

Ang II binding and Activation of AT1R

Modification of Ang II, site-directed mutagenesis and crosslinking studies established
the interactions between Ang II (DRVYIHPF) and AT1R (Fig. 1.5). The ligand binding
pocket formed by the hydrophilic TM domain residues is shown in Fig. 1.6 A. There are
two salt bridges, one between Arg2 of Ang II and Asp281 of AT1R and second between
the carboxyl group of Ang II and Lys199 of AT1R (Yamano et al, 1992, Noda et al, 1995,
Feng et al, 1995, Lefkowitz et al, 1993). The Asp1 of Ang II forms an ion pair with His183
in the ECL2 of AT1R (Feng et al, 1995). The aromatic stacking interactions between
Phe8 of Ang II and His256 of AT1R (Noda et al, 1995) and between Tyr4 of Ang II and
Asn111 of AT1R (Noda et al, 1996, Miura et al, 1998, Miura et al, 1999) were shown to
be critical not only for ligand docking but also for receptor activation (Fig. 1.6 B).
Crosslinking has shown two additional interactions, one between Phe8 of Ang II and
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Figure 1.5. Specific interactions of AT1R with Ang II and losartan. Secondary
structure model of rat AT1R, showing the interactions of AT1R with Ang II, previously mapped
by site directed mutagenesis (blue) and cross linking experiments (red). The AT1R residues
interacting with losartan are shown in yellow.
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Figure 1.6. Ang II binding to AT1R. A) Orientation of hydrophobic (magenta) and
hydrophilic (cyan) side chains in the rat AT1R. Both membrane plane view and
extracellular view is shown. (from Gogonea et al, 2006) B) The predicted hormonebinding site. Both membrane plane view and extracellular view is shown. Ang II in the
binding site is shown in space filling model, with Phe8 (magenta), Tyr4 (orange) and other
side chains (green) (from Gogonea et al, 2006). C) Replacement of water molecules in
the ligand binding pocket in the empty state of the AT1R by Tyr4 side chain of Ang II,
interacting with Asn111 in the active state of AT1R, as shown (from Husain and Graham,
2000).
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A)

B)

C)
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Phe293 and Asn294 in TMVII of AT1R (Perodin et al, 2002), the other between Val3 of
Ang II and Ile172 in the ECL2 region of the AT1R (Boucard et al, 2000). Thus, the
hydrophobic C-terminal region of Ang II appears to enter the TM core of the receptor.
The N-terminal region of Ang II is positioned towards the extracellular region of the
AT1R.

Several Ang II analogs have been generated by modification of Ang II side chains
to evaluate the effects on ligand binding and receptor activation (Miura and Karnik,
1999a). Ligand modification led to the identification of agonists, partial agonists and
antagonists. For example, modification of either Tyr4 or Phe8 side chains of Ang II
converts the agonist function into an antagonist function (Samanen et al, 1989). The
effect of substitutions of Tyr4 or Phe8 side chains on receptor binding and activation has
been further investigated by Miura et al (1999b). The aromatic side chains of these
residues have been shown to be critical switches for G-protein activation (Fig. 1.6 C).
Several other analogs retained partial agonist function. For example, [Ile4, Ile8] Ang II
functions as a selective ligand, which does not lead to receptor internalization and
stimulates β-arrestin dependent activation of ERK1/2 phosphorylation independent of Gq
(Feng et al, 1998). The discovery of non-peptide Ang II antagonists and derivatives has
significant therapeutic value. These antagonists have a structural pharmacophore similar
to Ang II which enables them to compete with Ang II for binding to AT1R and to
displace bound Ang II from the AT1R (Fig. 1.7 A). Losartan is a surmountable antagonist
of AT1R which can be displaced by Ang II; however, carboxylated derivatives of
losartan such as EXP3174, candesartan and irbesartan are insurmountable inhibitors. The
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Figure 1.7. Chemical structures of the Ang II and AT1R non-peptide antagonists. A)
Ang II and losartan pharmacophores (from Noda et al, 1995). B) Chemical structures of
EXP3174, candesartan, and olmesartan. All compounds have biphenyltetrazole and
imidazole groups. EXP3174, candesartan, and olmesartan, but not losartan, have a
carboxyl group. Only olmesartan has a hydroxyl group (from Miura et al, 2006).

A

B
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carboxylate group of these inhibitors provide an additional interaction with Gln257 of
AT1R (Fig. 1.7 B) (Vanderheyden et al, 2000, Takezako et al, 2004). The structure of
non-peptide antagonists mimics the contact points of Ang II side chains, and their binding
sites overlap with the Ang II binding pocket in AT1R as shown by mutagenesis and
crosslinking experiments (Yamano et al, 1992, Noda et al, 1995, Ji et al, 1995). For
example, Lys199 of AT1R forms a salt bridge interaction with both the carboxyl group of
Ang II and the tetrazole group of losartan (Fig. 1.8).

Upon Ang II binding, activation of AT1R is shown to be associated with
movements of TMII, TMIII, TMV, TMVI and TMVII (Fig 1.9) which is probably
conserved in rhodopsin family GPCRs (Miura et al, 2002&2003, Boucard et al,2003,
Martin et al, 2004 & 2007, Domazet et al, 2009). The disulfide bond linking TMIII and
ECL2 is highly conserved in more than 90% of GPCRs and has been suggested to have a
role in coupling the movements of TM helices to the ECL2 during receptor activation
(Karnik et al, 2003). Whether the ECLs play any role in the transition from inactive to
active state is not known. The role of ECLs in regulating the actions of agonists and
antagonists has not been studied in any GPCR.

We proposed a model of GPCR activation that involves the movement of ECL2,
which results in the movements of transmembrane domains (Karnik et al, 2003). Our
model is based on the findings that (i) the length of ECL2 in GPCRs is conserved; (ii)
electrostatic and hydrophobic interactions between different TM helices and ECL2 are
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Figure 1.8. Overlapping binding pockets of Ang II and losartan. A) Experimentally
mapped Ang II binding residues. B) Overlap of Ang II (red) and losartan (yellow)
interacting residues.

A)

B)
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Figure 1.9. Activation of AT1R. The transmembrane domains, TMII, TMIII, TMV,
TMVI and TMVII, that undergo conformational change upon AT1R activation are shown
in box. The highly conserved disulfide bond between TMIII and ECL2 is shown in
yellow.
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predicted in almost all GPCR models; (iii) a highly conserved disulfide bond links the
ECL2 to TM3 in 92% of GPCRs, and this disulfide bond is required for the structural
integrity and function in GPCRs examined; and finally (iv) the available crystal structures
of GPCRs confirmed the interaction of ECL2 with TM domains and the ligand.

Our proposal is further supported by observations reported by other investigators.
These studies suggested significant interaction of ECL2 with Ang II and TM-helices.
Two ECL2 residues, Ile172 and His183, have been shown by ligand cross linking and
mutagenesis to directly interact with Ang II (Feng et al, 1995, Boucard et al, 2000).
Mutagenesis of Glu173 in ECL2 leads to increased sensitivity to a partial agonist,
CGP42112A, implying that Glu173 chain imposes a constraint for activation in the
absence of ligand (Parnot et al, 2000). In addition, mutational studies in our laboratory
indicate that Phe182 in ECL2 is quite important for antagonist binding (unpublished
observations). Recently, AT1R activating antibodies directed against ECL2 were found in
preeclamptic patients (Wallukat et al, 1999, Zhou et al, 2008) and patients with refractory
vascular allograft rejection (Dragun et al, 2005). This suggests that ECL2 plays a role in
governing the active state of the AT1R. Therefore, interactions of the ECL2 with TM
domains may be important to guide ligands to the binding pocket and to regulate the
ligand dependent activation of the receptor.

1.3 The Extracellular Loop 2 in other GPCRs
Crystallographic structures and accumulating structure-function studies suggest
an unanticipated canonical role for ECL2 in ligand-induced activation of GPCRs. ECL2
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in the prototypical GPCR, bovine rhodopsin (Fig. 1.10 A), adopts a β-hairpin structure
that projects into the site of covalently bound retinal as ‘a stable lid’ directly interacting
with the ligand (Palczewski et al, 2000, Park et al, 2008). Upon light activation ECL2
moves away (Ahuja et al, 2009). Absence of a similar ‘lid’ in the recently solved
structures of GPCRs suggests that a path for diffusible ligands to the binding pocket may
be a specialization that evolved in other GPCRs. The ECL2 in β2 and β1 adrenergic
receptors (Fig. 1.10 B & C) has an α-helical conformation stabilized by an intra-loop
disulfide bond (Cherezov et al 2007, Warne et al, 2008). The ECL2 of A2A adenosine
receptor (Fig. 1.10 D) with three disulfide bonds is unstructured (Jaakola et al, 2008).
Despite these variations, all GPCR structures predict that ECL2 is a part of the ligand
binding pocket. ECL2 makes direct contacts with bound inverse agonist, 11-cis-retinal in
rhodopsin (Ser186 to Ile189, Glu181 and Tyr191), the antagonist cyanopindolol in β1
adrenergic receptor (Thr203 and Phe201), the inverse agonist carazolol in β2 adrenergic
receptor (Phe193) and the antagonist ZM241385 in A2A adenosine receptor (Phe168 and
Glu169). Positioned at the entrance to the binding cavity, ECL2 may regulate the access of
ligands and receptor activation in rhodopsin-like and other GPCR families (Bourne and
Meng, 2000).

The contribution of ECL2 in ligand binding and receptor activation has been shown
for many GPCRs such as dopamine D2 receptor (Shi and Javitch, 2004), the adenosine
A2A receptor (Jeongho et al, 1995), the M2 and M3 muscarinic acetylcholine receptor
(Anu et al, 2004, Scarselli et al, 2007), adrenergic receptors (Zhao et al, 1996) and the
histamine H1 receptor (Andrea et al, 2008). Importantly, some mutations on the ECL2
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Figure 1.10. The ECL2 structures in crystal structures of GPCRs. A) ECL2 structure
in Rhodopsin (from Cherezov et al, 2007). B) ECL2 structure in β2 adrenergic receptor
(from Cherezov et al, 2007). C) ECL2 structure in β1 adrenergic receptor (from Warne et
al, 2008). D) ECL2 structure in A2A adenosine receptor (from Jaakola et al, 2008).
Disulfide bonds are shown in yellow.
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led to constitutively active mutants in several GPCRs such as thyrotropin (TSH) receptor
(Duprez et al, 1997) and complement C5A receptor (Klco et al, 2005), indicating that the
ECL2 stabilizes the inactive conformation of these receptors. Importantly, receptoractivating auto-antibodies against the ECL2 regions have been discovered in several
human pathologies related to muscarinic receptors (Borda et al, 2004), β1 and β2
adrenergic receptors (Magnusson et al, 1994, Lebesgue et al, 1998) and the bradykinin
B2 receptor (Abdalla et al, 1995). Therefore, it is very important to study the structure of
ECL2 in detail.

Accumulating evidence suggests that the extracellular domain of AT1R plays a
critical role in guiding Ang II and ARBs to bind to TM helices, but the molecular details
are unclear. Based on molecular modeling and dynamic simulation studies, the AT1R
structure differs from both rhodopsin and adrenergic receptors in several key aspects.
Unlike rhodopsin which has covalently attached ligand, the AT1R has a diffusible ligand
similar to the ligand of adrenergic receptors. AT1R is different from the adrenergic
receptors due to the absence of additional intraloop disulfide bond. Therefore, AT1R may
have a different mechanism of structural stabilization. Molecular dynamic simulation
studies performed on the AT1R model predicted significant movement of ECL2, which is
seen in open and closed conformational states. Thus, ECL2 is likely a pivotal structural
element in generating different conformational states of AT1R, but the role it plays in
reversible binding of ligands is unknown.
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1.4 Significance of Current Work
Evidence based on both biochemical studies and molecular modeling of AT1R
suggests a critical role for ECL2 of AT1R in fundamental processes of ligand-mediated
activation and inhibition of the receptor. Elucidating the conformational regulation of
ECL2 by different types of ligands may help us dissect the pathophysiological processes
mediated by AT1R. In this study, we examine the conformation of ECL2 of the AT1R
specifically in basal, Ang II-bound and ARB-bound states by reporter-cysteine
accessibility mapping (RCAM). RCAM analysis allows us to systematically map the
surface accessibility of residues in a particular region of the receptor. RCAM involves
site-directed mutagenesis to introduce cysteine residues at selected positions within the
protein (Akabas et al, 1992). The reactivity of the introduced cysteines toward
hydrophilic, thiol specific, alkylating reagents is the basis for determining their surface
accessibility. The MTS reagents selectively and rapidly react with thiols (sulfhydryls) of
water accessible cysteines. The reactivity of MTS reagents with a cysteine in the water
accessible surface of a protein is much faster than one in the membrane or the protein
interior. Thus, RCAM can give information on whether a cysteine at a particular position
is buried or exposed (Fig. 1.11).

Our accessibility mapping analysis of ECL2 of AT1R in different states of the
receptor has indicated a ligand-induced conformational change in the ECL2. The highly
accessible ECL2 of AT1R is rendered inaccessible upon binding to agonist and
antagonist. Molecular dynamic simulations based on the accessibility constraint reveal an
open conformation of ECL2 in the empty receptor that may facilitate capture of Ang II,
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Figure 1.11. Schematic representation of ligand interference and ligand protection
assay.
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losartan and autoantibodies. A lid conformation of ECL2 is shown in both Ang II- and
losartan-bound states. The ligand-induced lid conformation of ECL2 may slow down the
dissociation of ligands and prolong the bound conformation. Conformational dynamics of
ECL2 may regulate ligand mediated processes in AT1R. These dynamic studies are
essential to improve remedies targeting AT1R for treatment of hypertension, heart failure
and end organ damage due to high blood pressure.

Our results have shown two different conformations of ECL2, open and closed
conformations, where the open conformation seems ideal for facilitating autoantibody
binding to AT1R. Autoantibodies have been shown to activate AT1R in several diseases,
including preeclampsia and vascular allograft rejection (Liao et al, 2002, Dragun et al,
2005, Zhou et al, 2008). Haptens specific for the open conformation of ECL2 can be
designed to prevent autoantibody interaction with the AT1R and block the immune
response against these autoantibodies in patients with these diseases.

Our findings are significant in the context of the whole GPCR family of proteins.
The ligand induced conformational changes of ECL2 shown in AT1R, which is a
rhodopsin family GPCR, might have useful implications for other GPCR families, such
as adhesion family GPCRs, for which there are no available antagonists. Novel agents or
modifications could be developed to disrupt interaction of ECL2 with their long Nterminal tails as a mechanism to inactivate these GPCRs.
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Specific conformational changes induced by agonist and antagonist binding
provides an experimental basis for further analysis of the effects of various ARBs on
AT1R dynamics and will aid in determining the high-resolution crystal structure of an
ARB-bound AT1R.

39

CHAPTER II
MATERIALS AND METHODS

2.1 Construction of Plasmids
The hemagglutinin (HA)-tagged AT1R gene was cloned into the shuttle
expression vector, pMT3, which contains unique EcoR1 and Not1 restriction sites (Fig.
2.1 A). The synthetic rat AT1R gene is flanked by EcoR1 restriction site on the 5’ end
and Not1 restriction site on the 3’ end. N-terminal HA epitope tag was introduced at the
5’ end of the gene by polymerase chain reaction (PCR) amplification in the presence of
FailSafe enzyme (Epicentre Biotechnologies, WI) using 10 pmol/µl of EcoR1-HA sense
primer and 10 pmol/µl of Not1 antisense primer (Fig. 2.1 B). The sequence was
confirmed by automated DNA sequencing (Fig. 2.2).

CYS¯AT1R was generated by PCR mutagenesis as described previously (Miura
et al, 2002 & Miura et al, 2003). Briefly, single residue mutations were introduced by
mismatched primer method and combined with PCR amplification. Primers were
designed to change cysteine residues at positions 76, 121, 144, 289, 296 and 355 into
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Figure 2.1. Cloning of HA-AT1R gene in pMT3 expression vector. A) Schematic
representation of pMT3 cloning vector. SV40, origin of replication; AdMLP, adenovirus
major late promoter; TPL, tripartite leader sequence; IVN, intervening sequence; EcoR1Not1, cloning sites for expression; DHFR, dihydrofolate reductase promoter; VA1,
adenoviral VA1 gene; pBR-ori1, origin of replication; AmpR; ampicillin resistance. B)
Schematic representation of cloning of PCR amplified HA-AT1R gene into pMT3 vector.
Primers used for PCR amplification are EcoR1-HA sense primer “CGGGAATTCGCCA
CCATGTACCCATACGACGTCCCAGACTACGCGGCCCTTAACTCTTCT”
Not1

antisense

primer

and

“CCCCCGCGGCCGCCTATTAAGCTGGAGCAACTTG”.

Template used was pcDNA3-AT1R. The parameters used for PCR reaction were an
initial denaturing step of 5 min at 94 °C followed by 30 cycles of 94 °C for 1 min, 60 °C
for 1 min and 72 °C for 1 min and then a final extension at 72 °C for 10 min.
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Figure 2.2. Nucleotide and amino acid sequence of HA-AT1R. The introduction of
HA epitope into AT1R gene is verified by sequencing. Red, EcoR1 restriction site;
Green, sequence encoding HA epitope; blue, stop codons; magenta, Not1 restriction site,
yellow, cysteine codons and residues. Disulfide bonded cysteines are framed.

HA-AT1R Nucleotide Sequence
GAATTCGCCACCATGTACCCATACGACGTCCCAGACTACGCGGCCCTTAACTCTTCTG
CTGAAGATGGTATCAAAAGGATCCAAGATGACTGCCCGAAGGCTGGACGTCACAGTTA
CATATTTGTCATGATTCCTACCCTCTACAGCATCATCTTTGTGGTGGGAATATTTGGA
AACTCACTAGTGGTGATTGTCATTTACTTTTACATGAAGCTGAAGACTGTGGCCAGCG
TCTTTCTTCTCAATCTCGCCTTGGCAGATTTATGCTTTTTGTTAACTTTGCCCCTGTG
GGCAGTCTATACCGCCATGGAGTACCGCTGGCCCTTCGGTAACCACCTATGTAAGATC
GCTTCGGCCAGCGTGAGCTTCAACCTCTACGCGTCTGTGTTCCTTCTCACTTGTCTCA
GCATCGACCGCTACCTGGCCATCGTGCACCCAATGAAGTCTCGCCTACGTAGAACGAT
GCTGGTGGCCAAAGTAACCTGCATCATCATCTGGCTGATGGCTGGCTTGGCTAGTTTG
CCTGCAGTCATCCACCGAAATGTATACTTCATCGAGAACACCAATATCACAGTGTGCG
CATTTCATTATGAGTCTCGAAATTCGACGCTCCCGATCGGGCTGGGCCTTACCAAGAA
TATACTGGGCTTCTTGTTCCCTTTCCTTATCATTCTCACCAGCTATACCCTCATATGG
AAAGCTCTAAAGAAAGCTTATGAAATTCAAAAGAACAAACCAAGAAACGATGACATCT
TTCGAATAATTATGGCGATTGTGCTTTTCTTCTTCTTTTCTTGGGTACCCCACCAGAT
ATTCACTTTCCTGGATGTGCTGATTCAGCTGGGCGTCATCCATGACTGTAAAATTTCT
GACATCGTGGACACTGCCATGCCCATCACGATATGCATAGCGTATTTTAACAACTGTT
TAAACCCTCTGTTTTACGGCTTTCTGGGGAAGAAATTCAAAAAGTACTTCCTCCAGCT
CCTGAAATATATTCCCCCGAAGGCCAAGTCCCACTCGAGCCTGTCTACGAAAATGAGC
ACGCTTTCTTACCGGCCTTCGGATAACATGAGCTCATCGGCCAAAAAGCCTGCGTCTT
GTTTTGAGGTGGAGTAATAGGCGGCCGC
HA-AT1R Amino Acid Sequence
MYPYDVPDYAALNSSAEDGIKRIQDDCPKAGRHSYIFVMIPTLYSIIFVVGIFGNSLVV
IVIYFYMKLKTVASVFLLNLALADLCFLLTLPLWAVYTAMEYRWPFGNHLCKIASASVS
FNLYASVFLLTCLSIDRYLAIVHPMKSRLRRTMLVAKVTCIIIWLMAGLASLPAVIHRN
VYFIENTNITVCAFHYESRNSTLPIGLGLTKNILGFLFPFLIILTSYTLIWKALKKAYE
IQKNKPRNDDIFRIIMAIVLFFFFSWVPHQIFTFLDVLIQLGVIHDCKISDIVDTAMPI
TICIAYFNNCLNPLFYGFLGKKFKKYFLQLLKYIPPKAKSHSSLSTKMSTLSYRPSDNM
SSSAKKPASCFEVE
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alanine. Please note that different cysteine codons were used to avoid potential
consequence of high abundance of a single codon during translation. The PCR products
were fractionated on agarose gel, isolated by QIAquick Gel Extraction Kit (QIAGEN
Sciences, Maryland), digested with appropriate restriction enzymes and purified with
QIAquick PCR Purification Kit (QIAGEN Sciences, Maryland). The insert was
subcloned into the synthetic gene which was digested with appropriate restriction
enzymes at each step of mutagenesis. The schematic explanation of construction of
CYS¯AT1R is given in Figure 2.3. The sequence of HA-CYS¯AT1R was confirmed by
automated DNA sequencing.

The single cysteine mutants of ECL2 were generated using PCR mutagenesis as
described in Figure 2.4 A. Briefly, sense and antisense mutagenic primers,
complementary to the CYS¯AT1R sequence and carrying the nucleotide changes (TGC)
to produce the desired amino acid (cysteine), were designed to substitute each residue on
ECL2 one at a time. The list of primers is given in Table II.I. The mutagenic primers
along with EcoR1 and Not1 primers were simultaneously annealed to the denatured
pMT3-HA-CYS¯AT1R template in the first PCR reaction. The full-length construct was
obtained in the second PCR reaction by amplification with EcoR1 and Not1 primers. The
PCR products were fractionated on agarose gel, isolated by QIAquick Gel Extraction Kit
(QIAGEN Sciences, Maryland), digested with EcoR1 and Not1 and purified with
QIAquick PCR Purification Kit (QIAGEN Sciences, Maryland). The insert was ligated
into pMT3, digested with EcoR1 and Not1, and then transformed into competent DH5α
cells (Fig. 2.4 B). The plasmids were isolated using QIAGEN Plasmid Maxi kit
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Figure 2.3. Schematic representation of construction of CYS¯AT1R. Single cysteine
substitutions, C76A, C121A, C144A, C289A, C296A, C355A were created by
mismatched primer method and combined as shown by PCR amplification. Primers are
shown as arrows. (Courtesy, John Boros, Shin-ichiro Miura & S. Karnik)
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Figure 2.4. Construction of ECL2 single cysteine mutants. A) Schematic explains the
introduction of I172C substitution as an example. pMT3-HA¯CYS-AT1R was used as a
template for PCR mutagenesis. The first PCR reaction involved either EcoR1 primer with
I172C antisense primer or Not1 primer with I172C sense primer. The second PCR
reaction annealed and amplified the purified fragments of the first PCR reaction in the
presence of EcoR1 and Not1 primer. B) Left panel, PCR-1. Lane 1, EcoR1 & E173C
antisense primers (product size: 571 kb); Lane 2, Not1 & E173C sense primers (product
size: 613 kb); Lane 5, EcoR1 & N174C antisense primers (product size: 573 kb); Lane 6,
Not1 & N174C sense primers (product size: 608 kb); Lane 9, EcoR1 & T175C antisense
primers (product size: 577 kb); Lane 10, Not1 & T175C sense primers (product size: 605
kb). Lanes 3, 7 & 11, negative control without template. Right panel, PCR-2 with EcoR1
& Not1 primers. Lane 1, E173C PCR1 fragments of lanes 1 & 2 of left panel (product
size: 1.2 kb); Lane 5, N174C PCR1 fragments of lanes 5 & 6 of left panel (product size:
1.2 kb); Lane 9, T175C PCR1 fragments of lanes 9 & 10 of left panel (product size: 1.2
kb). Lanes 2, 3, 6, 7, 10, 11, negative controls without either fragments.
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B
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Table II.I. The list of primers used for single cysteine substitutions.
PRIMER
I172C sense
I172C antisense
E173C sense
E173C antisense
N174C sense
N174C antisense
T175C sense
T175C antisense
N176C sense
N176C antisense
I177C sense
I177C antisense
T178C sense
T178C antisense
V179C sense
V179C antisense
A181C sense
A181C antisense
F182C sense
F182C antisense
H183C sense
H183C antisense
Y184C sense
Y184C antisense
T185C sense
T185C antisense
S186C sense
S186C antisense
R187C sense
R187C antisense
N188C sense
N188C antisense
S189C sense
S189C antisense
T190C sense
T190C antisense
L191C sense
L191C antisense
P192C sense
P192C antisense

SEQUENCE
GTATACTTCTGCGAGAACACC
GGTGTTCTCGCAGAAGTATAC
GTATACTTCATCTGCAACACCAATATC
GATATTGGTGTTGCAGATGAAGTATAC
CTTCATCGAGTGCACCAATATCAC
GTGATATTGGTGCACTCGATGAAG
CATCGAGAACTGCAATATCACAGTG
CACTGTGATATTGCAGTTCTCGATG
CGAGAACACCTGCATCACAGTGTG
CACACTGTGATGCAGGTGTTCTCG
GAACACCAATTGCACAGTGTGCGC
GCGCACACTGTGCAATTGGTGTTC
CACCAATATCTGCGTGTGCGCATTTC
GAAATGCGCACACGCAGATATTGGTG
CCAATATCACATGCTGCGCATTTC
GAAATGGCGAGCATGTGATATTGG
CACAGTGTGCTGCTTTCATTATGAG
CTCATAATGAAAGCAGCACACTGTG
CAGTGTGCGCATGCCATTATGAGTC
GACTCATAATGGCATGCGCACACTG
GTGCGCATTTTGCTATGAGTCTCG
CGAGACTCATAGCAAAATGCGCAC
GCATTTCATTGCGAGTCTCGAAATTC
GAATTTCGAGACTCGCAATGAAATGC
GCATTTCATTATTGCTCTCGAAATTCG
CGAATTTCGAGAGCAATAATGAAATGC
CATTATGAGTGCCGAAATTCGACG
CGTCGAATTTCGGCACTCATAATG
CATTATGAGTCTTGCAATTCGACG
CGTCGAATTGCAAGACTCATAATG
GAGTCTCGATGCTCGACGCTCCCG
CGGGAGCGTCGAGCATCGAGACTC
GTCTCGAAATTGCACGCTCCCGATC
GATCGGGAGCGTGCAATTTCGAGAC
CTCGAAATTCGTGCCTCCCGATCG
CGATCGGGAGGCACGAATTTCGAG
GAAATTCGACGTGCCCGATCGGGC
GCCCGATCGGGCACGTCGAATTTC
GAAATTCGACGCTCTGCATCGGGCTG
CAGCCCGATGCAGAGCGTCGAATTTC
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bp
21
21
27
27
24
24
25
25
24
24
24
24
26
26
24
24
25
25
25
25
24
24
26
26
27
27
24
24
24
24
24
24
25
25
24
24
24
24
26
26

%GC
47.62
47.62
37.04
37.04
45.84
45.84
44.00
44.00
54.17
54.17
54.17
54.17
50.00
50.00
45.84
45.84
44.00
44.00
52.00
52.00
50.00
50.00
42.31
42.31
37.04
37.04
45.84
45.84
41.67
41.67
66.67
66.67
56.01
56.01
58.34
58.34
62.5
62.5
57.70
57.70

TM
75.74
75.74
80.92
80.92
84.55
84.55
84.68
84.68
88.97
88.97
92.10
92.10
93.43
93.43
89.13
89.13
84.80
84.80
91.31
91.31
88.73
88.73
89.41
89.41
88.17
88.17
88.23
88.23
84.56
84.56
95.83
95.83
94.06
94.06
94.83
94.83
97.90
97.90
97.10
97.10

(QIAGEN Sciences, Maryland). The agarose gel fractionation of CYS¯AT1R and 20
single cysteine mutants is shown in Figure 2.5. All receptor mutants were confirmed by
automated DNA sequencing.

2.2 Cell Culture and Transfection
For expression in mammalian cells, we used COS1 cell line (American Type
Culture Collection, Rockville, MD) which is a green monkey kidney fibroblast cell line.
This cell line has been transformed with the large T antigen of SV40 which also
immortalizes the cell line. High levels of expression can be achieved transiently by
transfecting COS1 cells with plasmids that carry the SV40 origin of replication. COS1
cells were grown and maintained in Dulbecco’s modified Eagle’s medium (DMEM)
supplemented with penicillin/streptomycin and 10% fetal bovine serum. Cell cultures
were incubated at 37 °C in 5% CO2.

COS-1 cells were grown in 100-mm culture dishes to approximately 60-70%
confluence and transiently transfected by FuGENE 6 Transfection Reagent (Roche
Applied Science, IN) according to manufacturer’s instructions. Briefly, 18 µl of FuGENE
6 reagent was added into 600 µl of OPTI-MEM reduced serum media. 6 µg plasmid
DNA was then added and incubated for 15 min at room temperature. The mixture was
then added into the culture medium. The transfection efficiency was 40-50 % as
determined by transfection of cells with a plasmid encoding both AT1R and green
fluorescent protein (GFP) (Fig. 2.6).
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Figure 2.5. The agarose gel fractionation of HA-CYS¯AT1R and 20 single cysteine
mutants. 2 µg plasmid DNA is dissolved in H2O in a total volume of 20 µl. 4 µl of 6X
loading dye (Promega, WI) is added. M, 2 µl of 1 Kb Plus DNA ladder (Invitrogen)
mixed with 14 µl of TE buffer and 4 µl of 6X loading dye. Samples were run on 1 %
agarose gel at 90 Volts.
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Figure 2.6. Transfection efficiency in COS1 cells. A) Phase picture of COS1 cells
(Magnification X10). B) COS1 cells transfected with pEGFP-AT1R (Magnification
X10). The transfection efficiency was estimated by a rough count of [number of GFP
cells/number of DAPI stained cellsx100%].
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2.3 Western Blotting
After 48 hours incubation, transfected cells were placed on ice and washed twice
with ice-cold phosphate buffered saline (PBS). Cells were scraped and transferred into
centrifuge tubes and spun at 3900 rpm for 5 min at 4°C. Cells were lysed in Mammalian
Protein Extraction Reagent (MPER, 25mM bicine, CHAPS and N-tetradecyl-N, Ndimethyl-3-ammonia-1 propanesulfonate) (Pierce) containing protease (Sigma) and
phosphatase inhibitors (Thermo Scientific) with continuous rotation at 4°C for 25 min.
The lysate was centrifuged at 13200 rpm for 10 min at 4°C and the supernatant was
analyzed for protein concentration by Bradford method (Bradford, 1976) using bovine
serum albumin (BSA) as a concentration standard. 50 μg of protein from each sample
was incubated with 4X NuPAGE LDS sample buffer (Invitrogen) containing 10% 2mercaptoethanol at room temperature for 5 min and resolved on 10% sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (Invitrogen) and electroblotted
onto nitrocellulose membrane (0.45 µm) (Bio-Rad). The membrane was blocked in
blocking buffer (PBS with 0.5 % Tween-20 and 5% nonfat dried milk) for 1 hour at room
temperature. The membrane was then incubated with mouse anti-HA monoclonal
antibody (Roche) (1:1000) in blocking buffer at 4°C for overnight. The membrane was
washed three times for 10 min each with PBST (PBS containing 0.5 % Tween-20) and
incubated with HRP-conjugated anti-mouse IgG (GE Healthcare) (1:5000) in blocking
buffer for 1 hour at room temperature. The membrane was washed and the receptor
expression was detected using ECL Plus western blotting detection system (Amersham).
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2.4 Immunocytochemistry
24 hours post-transfection, cells were plated onto poly-L-lysine coated coverslips
placed in 6-well culture dishes. Cells were cultured for 24 hours in DMEM supplemented
with 10% fetal bovine serum and switched to serum-free DMEM 18 h before treatment.
Cells were fixed with 4% paraformaldehyde in PBS for 30 min and washed three times
with PBS for 10 min each. Cells were then permeabilized with 0.3% Triton X-100 in PBS
for 20 min on ice and blocked with 5% nonfat dry milk in PBS for 1 hour at room
temperature. Cells were incubated overnight with mouse anti-HA monoclonal antibody
(1:1000) in blocking buffer at 4°C, washed and incubated with AlexaFlour 568 antimouse antibody (1:2000) for 1 hour at room temperature in the dark. Cells were then
washed and mounted on coverslips on glass slides for confocal microscopy analysis.

2.5 Saturation Binding Assays
72 hours post-transfection, cells were placed on ice and washed twice with ice
cold PBS. Cells were gently scraped and transferred into centrifuge tubes and spun at
1000 rpm for 5 min at 4 °C. Cells were gently resuspended in binding buffer (140 mM
NaCl, 5.4 mM KCL, 1mM EDTA, 0.006% BSA, 25 mM HEPES, pH 7.4). Protein
concentration was determined by Bradford method (Bradford, 1976) using BSA as a
concentration standard. Binding assays were performed under equilibrium conditions,
with [125I]-[Sar1,Ile8] Ang II (Dr. Robert Speth, University of Mississippi) concentrations
ranging between 0.125-12 nM (specific activity: 2176 Ci/mmol) for 1 hour at room
temperature as previously described (Noda et al, 1996, Miura et al, 2002 & Miura et al,
2003). Nonspecific binding was measured in the presence of 10-5M [127I]-[Sar1Ile8] Ang
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II (Bachem). 25 μl of binding buffer or [127I]-[Sar1Ile8] Ang II was mixed with 50 μl of
increasing concentrations of [125I]-[Sar1,Ile8] and 50 μl of cell suspension in total volume
of 125 μl. Each concentration was repeated in duplicates in 96-well plates. The cells were
harvested with Combi cell harvester (Skatron Instruments, Norway) by filtering the
binding mixture through Whatman GF/C glass fiber filters (102×256 mm), which were
extensively washed with washing buffer (20 mM sodium phosphate, 100 mM NaCl, 10
mM MgCl2, 1 mM EGTA, pH 7.2) . The bound ligand fraction was determined using
10/600 Apex gamma counter (Titertek Instruments) as the counts per minute (cpm)
remaining on the membrane. The binding kinetics was analyzed by nonlinear curve
fitting program LigandR which yields mean±S.D. for Kd and Bmax values.

2.6 Analysis of ERK Phosphorylation
48 hours post-transfection, cells were serum starved for 18 h and treated with 1
μM Ang II (Bachem) for 10 min at room temperature. Cells were washed twice with icecold PBS. Cells were lysed and immunoblotted as described above and the membrane
was blocked in blocking buffer (PBS with 0.5 % Tween-20 and 5% BSA) for 1 hour at
room temperature. The membrane was incubated overnight with phospho-ERK
42/44MAPK polyclonal antibody (Cell Signaling) (1:1000) in blocking buffer. The
membrane was then washed and incubated with HRP-conjugated anti-rabbit IgG (1:5000,
GE Healthcare) in blocking buffer for 1 hour at room temperature. Immunoreactivity was
detected using ECL Plus western blotting detection system. The membranes were
stripped and similarly analyzed for total ERK 42/44MAPK (Cell Signaling) reactivity.
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Results were used to correct pERK 42/44MAPK measurements for slight differences in
sample protein content.

2.7 Intracellular Calcium Measurement
Changes in cytoplasmic Ca2+ were measured using fluorescent calcium indicator
Fura-2 (excitation maximum 340 and 380 nm; emission maximum 510 nm) (Invitrogen)
(29). The principle of Ca2+ measurement assay by Fura-2 is explained in Figure 2.7. Cells
were grown on coverslips in 6-well culture dishes. 48 hours post transfection, cells were
loaded with 1 μm Fura-2 acetoxymethyl ester 2 in BSS-Ca2+ buffer (140 mM NaCl, 5
mM KCl, 1.2 mM MgCl2, 5.5 mM Glucose, 10 mM Hepes, 0.1% BSA and 2 mM CaCl2,
pH 7.4). After 30 min incubation at 37 °C cells were washed with BSS-Ca2+ to remove
the extracellular dye. Calcium measurements were done in single cells using an inverted
microscope (Zeiss Axiovert 135) connected to a CCD camera (Photon Technology
International). The data were collected at 1.5-s intervals and analyzed using Image Master
software (Photon Technology International). The release of intracellular Ca2+ in
individual cells was measured after exposure to 1 µM Ang II in BSS-Ca2+ by rapid
solution exchange. Results were presented as average changes in the ratio of Fura-2
fluorescence upon excitation at 340 nm and 380 nm and plotted using SigmaPlot.

2.8 MTSEA-biotin Labeling
MTSEA-biotin (N-biotinylaminoethylmethanethiosulfonate, Toronto Research
Chemicals) in powder was stored as desiccated, dissolved in DMSO and aliquots of 0.1M
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Figure 2.7. Intracellular Calcium measurement by Fura2. A) Fura-2 is a membrane
impermeable UV-excitable fluorescent calcium indicator. Fura2-acetoxymethyl (Fura2AM) is a membrane-permeable derivative of the Fura2. Once inside the cells, the
acetoxymethyl groups are removed by cellular esterases. Removal of the acetoxymethyl
esters traps Fura2 inside the cells. B) Fura2 is a ratiometric dye which is excited at
340 nm and 380 nm. The ratio of the emissions at 510 nm is directly correlated to the
amount of intracellular calcium.
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stock aqueous solutions were thawed just prior to use and kept on ice. Experiments were
repeated at least three times as described below. 48 h post-transfection, cells were washed
twice with PBS, harvested using non-enzymatic cell dissociation solution (Sigma) and
suspended in PBS. 500 μl aliquots of cells were incubated with 10 mM MTSEA-biotin at
25 °C for 30 min. The incubation time and MTSEA-biotin concentration were
standardized to obtain maximum signal strength (Fig. 2.8). The reaction was stopped by
diluting with cold PBS. Cells were spun at 3900 rpm for 5 min at 4 °C and resuspended
in NP40 lysis buffer [1% NP40, 20 mM Tris (pH 7.4), 137 mM NaCl, 20% glycerol, and
protease and phosphatase inhibitors]. Protein concentration was determined by Bradford
method (Bradford, 1976) using BSA as a concentration standard. 750 μg of protein was
incubated overnight with 4 μl of mouse anti-HA monoclonal antibody in lysis buffer. The
receptors were immunoprecipitated with Protein-G agarose beads (Millipore) by
continuous rotation for 2 hours at 4 °C. Beads were then washed four times with cold
PBS and proteins were extracted by heating at 70°C in NuPAGE LDS sample buffer for
10 min. Samples were immunoblotted as described above and probed with StreptavidinHRP (Amersham) according to manufacturer’s instructions. Biotinylation level of
receptors was determined using KODAK 1D 3.6. To control for the differences of
receptors’ expression levels, the same blot was reprobed with anti-HA antibody as
described above. MTSEA-biotin accessibility of each receptor was obtained by
normalizing the biotinylation level of each receptor to its expression level. The same
procedure was repeated following either 1 µM Ang II (Bachem) or 1 µM losartan
(DuPont Merck Co, Wilmington, DE) treatment for 10 min at room temperature (Fig
2.9).
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Figure 2.8. Assay standardization. A) Immunoprecipitation control experiment of HACYS¯AT1R (lane 1) and HA-AT1R (lane 3) with anti-HA antibody. Negative controls
lack anti-HA antibody (lanes 2 and 4). Untransfected cells are also shown as negative
controls. The fully glycosylated monomeric receptor band is shown by arrow. B)
Standardization of MTSEA-biotin concentration was performed with 2 mM, 5 mM and
10 mM MTSEA-biotin concentrations. C) Standardization of incubation time was
performed with 0-10 min time points using 10 mM MTSEA-biotin.
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Figure 2.9. Experimental strategy for MTSEA-biotin accessibility measurement.
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2.9 Molecular Dynamics Simulations
Molecular Dynamics (MD) simulations were performed using the MD software
package NAMD (Phillips et al, 2005) and the CHARMM 22. The modeled structure of
AT1R (PDB ID: 2AC6) and AT1R with Ang II (PDB ID: 2AH3) (Gogonea and Karnik,
2006) was downloaded from the Protein Data Bank, and explicit hydrogen were added
using the package VEGA ZZ 2.0.7 (Pedretti et al, 2004). This structure was subjected to
1000 steps of energy minimization. The energy-minimized system was heated from 0°C
to 310°C in 31°C intervals over the course of 20,000 steps. Simulations were carried out
for 14 ns. The root-mean-square deviation of the backbone of AT1R with Ang II was
stabilized after 7 ns. MD simulations were carried out using the molecular modeling
software VEGA ZZ 2.0.7. We simulated ECL2 residues (Ile165- Pro192) with selected loop
constraints and other receptor regions were not simulated. The ECL2 simulations were
carried out by imposing Cys
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-Cys180 disulphide bond as a constraint in different states. The

disulphide bond constraint was relaxed for 1 ns at the end of 14 ns simulation. We used PyMOL

(DeLano Scientific LLC) to visualize the output. A schematic explanation for steps of
MD simulation is given in Figure 2.10.

2.10 Losartan Docking
Blind docking was carried out using AutoDock4 Vina (Trott and Olson, 2009).
The starting conformation of losartan was an energy minimized form. The receptor was
held rigid during the docking process while the ligand was allowed to be flexible to save
computational time. The grid box size was 38.0A˚ -20.8A˚-26.4A˚ in the x, y and z
dimensions, with the center of the grid corresponding to the central axis of the pore at

60

Lys199 and His256 at the base of the selectivity filter. Exhaustiveness was set as default.
We used PyMOL to visualize the output.

2.11 Statistical Analysis
The results are expressed as the means ± Standard error of mean (SEM) and analyzed by
unpaired t test for statistical significance to compare variables between mutants and wild type
using Graphpad PrismR. Significance is set at p < 0.05.
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Figure 2.10. Schematic explanation of MD simulation procedure.
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CHAPTER III
HA-CYS¯AT1R

3.1 Introduction
The structural analysis of transmembrane proteins such as AT1R through direct
techniques, including x-ray crystallography and nuclear magnetic resonance (NMR)
spectroscopy has been challenging. AT1R is expressed at very low levels (40-80
fmoles/mg) in native tissues. In addition, the structural flexibility of AT1R causes
thermodynamic

and

proteolytic

instability

during

detergent-solubilization

and

purification. Many of these experimental constrains have been overcome by higher level
expression (>100-fold compared to native cells) of receptor genes in recombinant
systems. Increasing the level of expression of a GPCR often requires alteration of some
structural features, such as attachment of a signal sequence, introduction of stabilizing
mutations, or deletion of some segments of the receptor. Recombinantly expressed β2
adrenergic, β1 adrenergic and the adenosine A1 receptors have been crystallized. Thus,
protein engineering and recombinant expression of GPCRs has advanced the
understanding of structure-function relationships of GPCRs.
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Even when the high-resolution crystal structure is obtained, it represents a rigid,
single conformation of a GPCR. We need other approaches to address questions
concerning the dynamics and conformational changes associated with different states of
activation, which allow the receptor to interact with a variety of diffusible ligands and
generate diverse intracellular responses. Therefore we require additional indirect
techniques to elucidate the dynamic properties of GPCRs such as AT1R. We planned to
use a cysteine accessibility mapping approach to determine the dynamic changes in
AT1R in different states including unbound, agonist-bound and antagonist-bound states.
As described in Section 1.4, our accessibility mapping strategy requires introduction of
cysteine residues into the region of interest one-at-a-time and measurement of the level of
reactivity of engineered cysteines with thiol-specific alkylating reagents, which estimate
the water accessibility of each residue.

To effectively use this technique for AT1R, it would be ideal to construct a
receptor which lacks all non-disulfide bonded cysteine residues. AT1R has ten native
cysteines, four of which are disulfide bonded and six of which are not disulfide bonded
(Fig. 3.1). Two disulfide bonds in the AT1R are critical for maintaining the 7 TM
structure and the conformational changes associated with receptor activation/inhibition
(Ohyama et al, 1995, Feng et al, 2000). Disulfide bonded cysteines also do not react with
thiol-specific alkylating reagents. Some of the free cysteines may be buried during
folding of the receptor to the three dimensional structure and may not be accessible to the
thiol-specific alkylating reagents. However, one can not be sure if the buried cystines are
exposed during receptor activation or inhibition. The cysteines that are partially
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Figure 3.1. The secondary structure model of HA-CYS¯AT1R. Native non-essential
free cysteine residues, Cys76, Cys121, Cys144, Cys289, Cys296 and Cys355, substituted with
alanine are shown in green circles. Native cysteines involved in formation of essential
disulfide bonds, Cys18-Cys274 and Cys101-Cys180, are shown in gold circles.
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accessible might interfere with the accessibility measurements of engineered cysteines.
Therefore we created a receptor surrogate of HA-AT1R named as HA-CYS¯AT1R that
lacks all non disulfide-bonded cysteines. It is very important to rigorously characterize
the modified protein for functionality to be able to use it for mapping the conformation
associated with different states of the receptor. In this chapter we describe the
construction and characterization of HA-CYS¯AT1R. We show that pharmacological and
signal transduction properties of HA-CYS¯AT1R are similar to those of HA-AT1R.

3.2 HA-CYS¯AT1R Nucleotide Sequence Confirmation
The mutagenesis steps used in the construction of HA-CYS¯AT1R are
schematized in detail in Figure 2.1. In the HA-CYS¯AT1R, native cysteines involved in
the formation of disulfide bonds, Cys18-Cys274 and Cys101-Cys180, which are essential for
receptor stability (Ohyama et al, 1995 & Feng et al, 2000) were not mutated (Fig. 3.1).
The codons for these cysteine residues were unaltered (Table III.I). Codons for other
native non-essential free cysteine residues (Cys76, Cys121, Cys144, Cys289, Cys296 and
Cys355) were substituted with alanine codons. The substituted alanine codons in the HACYS¯AT1R that were confirmed by DNA sequencing are listed in Table III.I. A
comparison of nucleotide sequences of HA-AT1R and HA-CYS¯AT1R is shown in
Figure 3.2 for three representative alanine substituted cysteine codons; Cys76, Cys121 and
Cys149. The HA-CYS¯AT1R will serve as the background to introduce reporter cysteine
residues in the ECL2.
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Table III.I Cysteine substitutions in HA-CYS¯AT1R. HA-AT1R was subjected to
site-directed mutagenesis as described in Section 2.1, creating HA-CYS¯AT1R in which
6 of the 10 cysteine residues of HA-AT1R was substituted with alanine. DNA sequence
analysis confirmed C76A, C121A, C144A, C289A, C296A, C355A substitutions in
HA¯CYS-AT1R as shown. The codons for Cys18, Cys101, Cys180 and Cys274 which are
involved in disulfide bond formation were not modified as indicated in bold. The DNA
sequencing chromatogram for corresponding residues of HA-CYS¯AT1R is also shown.
Green, A; Red, T; Blue, T; Black, G.
HA-AT1R

HA¯CYS-AT1R

Codon change

Cys18

Cys18

TGC → TGC

Cys76

Ala76

TGC → GCC

Cys101

Cys101

TGT → TGT

Cys121

Ala121

TGT → GCT

Cys149

Ala149

TGC → GCC

Cys180

Cys180

TGC → TGC

Cys274

Cys274

TGT → TGT

Cys289

Ala289

TGC → GCC

Cys296

Ala296

TGT → GCT

Cys355

Ala355

TGT → GCA

67

Chromatogram

Figure 3.2. Comparison of chromatograms of HA-AT1R and HA¯CYS-AT1R. The
sequences of Cys76, Cys121 and Cys149 positions of HA-AT1R and the corresponding
alanine substitutions in HA¯CYS-AT1R are shown as an example. Green, A; Red, T;
Blue, T; Black, G.
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3.3 Characterization of HA-CYS¯AT1R
The expression of HA-AT1R and HA-CYS¯AT1R, compared by immunoblotting,
showed similar levels in transiently transfected COS1 cells. Both receptors appear to be
fully glycosylated (41.9 kDa). When analyzed by SDS-PAGE, unglycosylated (~37 kDa)
and partially glycosylated (~40 kDa) monomeric forms of the receptors as well as small
amounts of higher molecular weight oligomers (50-80 kDa) were present (Fig. 3.3 A) in
both. Other properties in terms of cell surface expression, cellular localization, binding
affinity for Ang II and agonist activated signaling were compared. Immunocytochemical
anlaysis indicated that both HA-AT1R and HA-CYS¯AT1R were expressed on the
plasma membrane at similar levels (Fig. 3.3 B). The Kd values of HA-AT1R and HACYS¯AT1R for the peptide antagonist

125

I-[Sar1, Ile8]Ang II, obtained by saturation

binding analysis performed on intact cells, were 3.5 nM and 4.4 nM, respectively (Fig 3.4
A). The cell surface Bmax values measured from scatchered plots were 3.5 pmol/mg and
5.8 pmol/mg for HA-AT1R and HA-CYS¯AT1R respectively (Fig. 3.4 B).

To analyze the Ang II-induced signal transduction capacity of HA-CYS¯AT1R, we
measured ERK1/2 activation and intracellular Ca2+ release upon 1 µM Ang II treatment
(Fig. 3.5 A). The level of ERK1/2 activation of HA-CYS¯AT1R was comparable to HAAT1R (Fig. 3.5 B). The Ang II-induced ERK1/2 activation was inhibited by the AT1Rselective non-peptide antagonist, losartan (Fig. 3.5 B). Ang II-induced mobilization of
intracellular calcium, which is a measure of G protein activation, was similar in HACYS¯AT1R and HA-AT1R (Fig. 3.5 C). These results suggested that cell surface
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Figure 3.3. Expression analysis of HA-AT1R and HA-CYS¯AT1R. A) Western blot
analysis of HA-AT1R (lane 4) and HA-CYS¯AT1R (lane 5) expression in COS1 cells.
Cells which are mock transfected (MT) (lane 1), transfected with pMT3 (lane 2) and
CYS¯AT1R without HA tag (lane 3) are shown as negative controls. The 64 kDa band
corresponds to a nonspecific, cross reacting protein. 3 differentially glycosylated
monomeric bands of the receptor are identified as fully-, partial- and single-glycosylated
bands. Higher molecular weight oligomeric forms of the receptor can be seen between
51-80 kDa. B) The localization of HA-AT1R (panel 2) and HA-CYS¯AT1R (panel 3) on
the plasma membrane of COS1 cells. Untransfected cells are shown as negative control
(panel 1). Cells were labeled with DAPI (blue) for nucleus and with mouse HA
monoclonal primary antibody and Alexa flour 568 (red) anti-mouse secondary antibody
for HA-tagged receptors. Plasma membrane is indicated by yellow arrow.
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Figure 3.4. Binding analysis of HA-AT1R and HA-CYS¯AT1R. A) Saturation curves
of HA-AT1R and HA-CYS¯AT1R determined using [125I]-[Sar1, Ile8] Ang II. Inset
shows the corresponding Scatchard plot. B) Cell surface density of HA-AT1R and HACYS¯AT1R expressed as mean Bmax values derived from Scatchard plots. Error bars
indicate the S.E.M., p=0.082 (n=3).
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Figure 3.5. Activity analysis of HA-AT1R and HA-CYS¯AT1R. A) The signal
transduction pathway of AT1R activated by Ang II binding. The intracellular Ca2+
release and MAPK activation were analyzed as read-out of Ang II induced activity. B)
ERK1/2 phosphorylation (p-ERK) upon treatment with 1 μM Ang II on untransfected
cells (lanes 1-2), HA-AT1R (lanes 3-4) and HA-CYS¯AT1R (lanes 7-8) transfected cells.
ERK1/2 phosphorylation is inhibited by losartan treatment prior to Ang II treatment (lane
5 & 9) and together with Ang II treatment (lane 6 & 10). Total ERK (t-ERK) levels are
shown as loading control. The plot corresponds to the p-ERK/t-ERK ratio of lanes
3,4,6,7,8,10. C) Measurement of intracellular Ca2+ mobilization upon 1 μM Ang II
treatment in HA-AT1R and HA-CYS¯AT1R transfected COS1 cells. The time point of
Ang II treatment is indicated by the arrow.
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expression, Ang II binding affinity, activation and inhibition properties of HACYS¯AT1R are comparable to those of wild type HA-AT1R.

3.4 Reaction of HA-AT1R and HA-CYS¯AT1R with Cysteine Reactive MTSEAbiotin
We anticipated that the HA-CYS¯AT1R would not react with thiol-specific
modifying

reagent,

MTSEA-biotin

(N-biotinylaminoethylmethanethiosulfonate).

MTSEA-biotin consists of a biotin moiety attached to the highly reactive
methanethiosulfanate. The MTSEA-biotin (Fig. 3.6 A) does not react with disulfide
bonded or buried cysteine residues, but rapidly reacts with water-exposed reactive
cysteines (Akabas et al, 1992).

O
Protein

O

SH + CH3 S S biotin

Protein S S biotin + CH3 S

O

H

O

The resulting site-specific covalent attachment of biotin (red) to engineered
cysteine was detected by streptavidin-HRP. Figure 2.9 explains the MTSEA-biotin
labeling strategy. The receptor topology was preserved during MTSEA-biotin reaction as
closely as possible to the native state in the plasma membrane by using adherent cells
rather than fractionated membranes.

The anticipated reaction of HA-AT1R and HA-CYS¯AT1R with MTSEA-biotin
is depicted in Figure 3.6 A. Theoretically; HA-AT1R carrying 6 free cysteines is
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expected to be six times more reactive to MTSEA-biotin compared to HA-CYS¯AT1R,
which lacks all the free cysteines. We compared the reactivity of HA-AT1R and HACYS¯AT1R with MTSEA-biotin (Fig. 3.6 B). Following MTSEA-biotin treatment,
detergent solubilized HA-tagged receptors were immunoprecipitated using anti-HA
antibody and probed with streptavidin-HRP. Band intensities observed by HA blot were
similar, which controls for expression levels of two receptors. Fully glycosylated
monomeric receptor band was monitored for the quantification (Fig. 3.6 C). The level of
biotinylation was estimated by normalizing the streptavidin-HRP signal to the HA signal
for each sample. MTSEA-biotin modification of HA-AT1R which has six native free
cysteines is ≈ 2-fold more than HA-CYS¯AT1R which lacks those cysteines (Fig. 3.6 D).
This result is consistent with the previous study by Miura & Karnik (2002), which
demonstrated that among the 6 native free cysteines in wild type AT1R, only Cys76 in
TMII of AT1R is fully reactive to MTSEA (Fig. 3.7). The native Cys289 and Cys296 were
partially reactive to MTSEA. The authors measured the MTSEA sensitivity of native
cysteine residues of the AT1R and individual Cys→Ala mutants. This data explains our
observation of 2-fold more reactivity of HA-AT1R compared to HA-CYS¯AT1R.

The results discussed in this chapter suggest that HA-CYS¯AT1R is functionally
similar to HA-AT1R. It appears that the disulfide bonds are formed appropriately and
maintain the stability of the HA-CYS¯AT1R as anticipated. The four disulfide bonded
cysteine residues in AT1R are sufficient for proper folding and maintenance of the
tertiary structure of the receptor polypeptide. It is quite impressive to observe that
replacing six free cysteines did not alter expression and affinity of the receptor for both
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Figure 3.6. MTSEA-biotin accessibity of HA-AT1R and HA-CYS¯AT1R. A) The
anticipated reaction of HA-AT1R which has 6 free cysteines with 6 MTSEA-biotin. B)
HA and Streptavidin-HRP blots comparing levels of expression and MTSEA-biotin
labeling, respectively. The band representing the fully-glycosylated, mature form of the
receptor that has been used for quantification of MTSEA-biotin relative accessibility is
shown in red box. C) The cropped image of panel A only indicates the receptor band that
has been used for quantification of MTSEA-biotin relative accessibility. D) The
corresponding plot shows the MTSEA-biotin relative accessibility which is the ratio of
Streptavidin-HRP signal intensity to HA signal intensity for particular sample. The red
line indicates the level of biotinylation of HA-CYS¯AT1R without any free cysteine
which is determined as the cut-off below which the reactivity is considered inaccessible.
The observed stoichiometry of the reaction is shown.
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Figure 3.7. Inhibition of ligand binding following reaction of MTSEA with AT1R
and CYS¯AT1R. A) Time course inhibition of specific binding of 125I-[Sar1, Ile8] Ang II
to the AT1R and mutant receptors, CYS¯AT1R, C76A, C289A and C296A after
treatment with 2.5 mM MTSEA. B) Dose response inhibition of specific binding to the
AT1R and mutant receptors, CYS¯AT1R, C76A and C289A after treatment with 2.5 mM
MTSEA. Details are given in references 5 and 7. In the wild type receptor, MTSEA
inhibited [Sar1,Ile8]Ang II binding whereas binding in the CYS¯AT1R and C76A mutant
was resistant to MTSEA reaction. Therefore, the inhibition of [Sar1, Ile8]Ang II binding is
due to reaction of MTS reagents with Cys76 in the TMII and the remaining free cysteine
residues are not accessible (from Miura & Karnik, 2002).
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agonist and antagonist. The Cys355 in AT1R is analogous to the cysteine residue that is
palmitoylated in rhodopsin and adrenergic receptors. The palmitoylated cysteine may
stabilize the C-terminal tail of the receptor by providing a pseudo cytoplasmic loop
(Sachs et al, 2000). However, the substitution of Cys355 with alanine did not affect the
stability and function of the AT1R in our study. In addition HA-CYS¯AT1R is less
sensitive to MTSEA-biotin compared to HA-AT1R. Therefore, we used the HACYS¯AT1R as a template to create 20 single cysteine substituted ECL2 mutants used in
our accessibility analysis.
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CHAPTER IV
CYSTEINE SCANNING MUTAGENESIS

4.1 Introduction
Chemical reactions that are rather specific for functional groups of each type of
amino acid side chain have historically played a significant role in the development of
foundational concepts of protein structure and function. Chemical modifications are
possible for several residues carrying reactive groups on their side chains, including
histidine, lysine, arginine, methionine, tryptophane, tyrosine and cysteine. Wider use of
chemical modification is hampered because modification reactions use harsh conditions
which may cause structural or conformational changes in the protein, affecting the
biological function. The thiol group of cysteine residues is one of the most versatile
functional groups, amenable to probing in terms of surface location or burial, location in
static or dynamic regions of proteins. The cysteine thiol group is the most reactive among
the functional groups of amino acids. Many reagents are available that specifically react
with thiol groups. Thiol groups can be modified through metal binding, acylation,
alkylation, cyanylation and oxidation under conditions that preserve the relevant
biological functions of proteins (Chalker et al, 2009).
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The advent of site-directed mutagenesis expanded the use of cysteine thiols as reporter
groups in defining details of protein structure, function and dynamics that are not easily
approachable by time-consuming methodologies including crystallography and NMR,
which also require very expensive instrumentation. In many instances the reporter
cysteine mapping is the only practical approach to study the protein in its native
microenvironment. Cysteine substitutions can be directed to any region of a protein. The
overwhelming experience is that the substituted cysteines are well tolerated in most
biological systems. In the study of TM receptors, cysteine scanning mutagenesis is the
method of choice because very few cysteine substitution mutants fail to yield functional
receptors on the cell surface. Thus, cysteine substitutions are very well tolerated (Kaback
et al, 1997).

In this chapter, we describe an extensive characterization of single cysteine
mutants in ECL2, a 20 residue long segment of the extracellular domain of AT1R with
poorly defined functions. It is necessary to ascertain that no gross conformational change
occurred in the AT1R upon each modification. Only cysteine substitution mutants with
near wild-type function can be used for further modification because we assume that the
substituted cystiene side chain has wild-type-like orientation and rotational freedom.

4.2 Expression Analysis of ECL2 Single Cysteine Mutants
The mutagenesis strategy used in the construction of ECL2 mutants is
schematized in detail in Figure 2.4. DNA sequencing confirmed that each native residue
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in ECL2 was substituted with a cysteine, one at a time. The substituted cysteine codons in
the ECL2 mutants are listed in Table IV.I.

The expression of each single cysteine substitution mutant upon transient
transfection of COS1 cells was determined by western blotting. Western blot analysis
showed that most of the mutant receptors were expressed at a similar level to that of HACYS¯AT1R. Transient transfection of 18 single cysteine mutant plasmids yielded ≈ 42
kDa fully glycosylated mature form of the functional receptor protein in COS1 cells (Fig.
4.1). Variable expression seen due to variability in transient transfection was not
statistically significant. Thus introduction of cysteine side chains at 18 different positions
of ECL2 in the AT1R did not significantly interfere with the overall folding and transport
to cell surface.

The expression level of mutant I177C was reduced and the V179C mutant
receptor protein appeared to be degraded. To understand the reasons for instability of
these two mutant receptors in COS1 cells, we carried out additional site directed
mutagenesis. Serine substitution for Ile177 significantly reduced the expression whereas
substitution of alanine was normal. This suggested that a hydrophobic residue is essential
at position 177 for normal expression of the receptor (Fig. 4.2). Substitution of both
serine and alanine for Val179 produced stable receptor protein, suggesting that the
cysteine side chain introduced at position 179 causes instability. The reasons for
instability of these mutant receptors are unclear. However, since Ile177 and Val179 are n-3
and n-1 positioned residues from conserved Cys180, the side chains of these residues may
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Table IV.I. Cysteine scanning mutagenesis of ECL2. HA-CYS¯AT1R was subjected
to oligonucleotide mediated site-directed mutagenesis, creating a series of 20 mutants in
which each of the 20 residues within ECL2 was individually changed to cysteine. The
native disulfide bonded cysteine is indicated in bold.

Residue no
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192

Amino acid change
Ile → Cys
Glu → Cys
Asn → Cys
Thr → Cys
Asn → Cys
Ile → Cys
Thr → Cys
Val → Cys
Cys → Cys
Ala → Cys
Phe → Cys
His → Cys
Tyr → Cys
Glu → Cys
Ser → Cys
Arg → Cys
Asn → Cys
Ser → Cys
Thr → Cys
Leu → Cys
Pro → Cys
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Codon change
ATC → TGC
GAG → TGC
AAC → TGC
ACC → TGC
AAT → TGC
ATC → TGC
ACA → TGC
GTG → TGC
TGC → TGC
GCA → TGC
TTT → TGC
CAT → TGC
TAT → TGC
GAG → TGC
TCT → TGC
CGA → TGC
AAT → TGC
TCG → TGC
ACG → TGC
CTC → TGC
CCG → TGC

Figure 4.1. Expression of ECL2 single cysteine mutants. Expression analysis of HACYS¯AT1R (lane 2) and HA-tagged single cysteine mutants (lanes 3-22) in transiently
transfected COS1 cells. Untransfected cells served as negative control (lane 1). ~42 kDa
band corresponds to the fully-glycosylated mature cell surface receptor. The multimeric
receptor bands are observed between 50-80 kDa. Actin expression levels are shown as
loading control.
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Figure 4.2. The expression analysis of Ile177 and Val179 mutants with cysteine,
alanine and serine substitutions.
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be important to define the structural context for Cys181 to form the disulfide with Cys101.
Non-tolerated mutations at these positions may change the stability of this disulfide bond
and the proper folding of the TM helices by increasing the energy of folding due to the
nature and orientation of the substituted side chain. The introduced cysteine side chain at
position 179 might directly interfere with the formation of the Cys101-Cys180 disulfide
bond or induce the formation of an abnormal disulfide bond resulting in an unstable
receptor polypeptide.

4.3 Effect of Cysteine Substitutions in ECL2
The cell surface receptor expression (Bmax) of twenty single cysteine mutants
measured in intact COS1 cells is shown in Table IV.II. Bmax values of mutants T178C,
H183C, R187C, N188C and L191C was within 5-fold and <20-fold for the remaining
mutants. The calculated cell surface receptor number shows that there are enough
receptors on the cell surface to perform RCAM analysis in mutants with lower Bmax
values, I177C, V179C, E185C and P192C. The calculated fold changes in Kd values for
mutants compared to HA¯CYS-AT1R suggested that all mutants bound the ligand with
high-affinity and specificity (Table IV.II). Binding of agonist Ang II elicited ERK1/2
activation response in all ECL2 mutants, demonstrating the capacity of mutants to
assume active conformation (Table IV.II). Ang II-induced ERK1/2 activation capacity
displayed by mutants E173C, T175C, E185C, S186C, S189C is reduced compared to
HA-CYS¯AT1R, however the reduction is not statistically significant (Table IV.II). The
antagonist losartan inhibited Ang II-dependent activation of all mutants.
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Table IV.II. Characterization of ECL2 single cysteine mutants.
Cell Surface Expression

ΔKd**

MAPK activation***

350,000

1.0

Yes

0.36 ± 0.07

21,500

1.3

Yes, p = 0.20

E173C

0.34 ± 0.03

20,600

1.4

Yes, p = 0.44

N174C

0.66 ± 0.05

40,000

1.4

Yes, p = 0.69

T175C

0.72 ± 0.01

43,000

1.4

Yes, p = 0.69

N176C

0.71 ± 0.12

43,000

1.3

Yes, p = 0.35

I177C

0.26 ± 0.05

15,800

1.3

Yes, p = 0.88

T178C

2.32 ± 0.32

139,600

1.6

Yes, p = 0.79

V179C

0.12 ± 0.02

7,500

2.3

Yes, p = 0.39

A181C

0.38 ± 0.03

22,700

2.1

Yes, p = 0.60

F182C

0.71 ± 0.11

42,800

1.4

Yes, p = 0.34

H183C

1.94 ± 0.47

116,700

1.4

Yes, p = 0.66

Y184C

0.34 ± 0.04

20,600

1.8

Yes, p = 0.54

E185C

0.11 ± 0.03

6,700

2.3

Yes, p = 0.51

S186C

0.91 ± 0.32

55,100

1.9

Yes, p = 0.55

R187C

6.50 ± 0.20

391,700

1.6

Yes, p = 0.51

N188C

3.36 ± 0.21

202,600

1.4

Yes, p = 0.35

S189C

0.78 ± 0.05

46,700

2.1

Yes, p = 0.69

T190C

0.61 ± 0.05

36,800

1.9

Yes, p = 0.98

L191C

1.59 ± 0.23

95,600

2.2

Yes, p = 0.90

P192C

0.03 ± 0.01

1,700

3.0

Yes, p = 0.68

HA-AT1R

3.5 ± 0.15

175,000

0.8

Yes, p = 0.65

Bmax (mean±SEM)

~Receptors/cell*

HA-CYS¯AT1R

5.80 ± 0.12

I172C

* Number of receptors on the cell surface calculated by the formula: [(Bmax*Avogadro’s
number) / number of cells].
** Kd value for HA-CYS ¯AT1R is 4.4 nM. Kd value for HA-AT1R is 3.5 nM.
*** MAPK activation indicates that ERK is phosphorylated upon treatment with 1µM Ang II,
demonstrating the ability of mutants to assume active conformation upon binding Ang II. Pvalues are derived from two-tailed, unpaired t-test.
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The results presented in this chapter suggest that, the single cysteine substitution
in the ECL2 region did not cause gross defect in the conformation which indicates that
substituted cysteine residue orientation is similar to that of the wild type residue at each
position.
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CHAPTER V
ACCESSIBILITY MAPPING ANALYSIS OF ECL2

5.1 Introduction
Variations of the site-directed cysteine labeling (modification) techniques have
been a very a powerful approach in structure-function studies of GPCRs. Site-directed
cysteine residues are used as sites for attachment of spin-label reporter groups (Loewen et
al, 2001), for binding metal ions or for inducing site-specific cross linking (Itoh et al,
2001, Cai et al, 2001) to unravel structural and dynamic features of functional motifs in
rhodopsin and other neuroendocrine GPCRs. Site-directed spin labeling studies pioneered
by Hubbell and Khorana (Farrens et al, 1996, Altenbach et al, 1996) employed sitedirected cysteine substitutions to analyze the folding and conformational dynamics.
Specific positions in receptors can be labeled with

13

C-methyl to facilitate structural

analysis by nuclear magnetic resonance (NMR) spectroscopy (Bokoch et al, 2010).
Sulfhydryl groups can be modified with specific reagents such as 2-nitrobenzoic acid
(DTNB) that enable spectrophotometric monitoring of the reaction (Yang et al, 1996).
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Methanethiosulfanate (MTS) reagents are more recently described thiol-specific
probes, which provide advantages due to their high selectivity and rapid reactivity with
the thiolate anion (S—) rather than the reduced -SH (Akabas et al, 1992). Only water
accessible cysteines ionize to thiolate and thus react with hydrophilic MTS reagents a
billion times faster than buried cysteines, which cannot ionize to a significant extent
(Roberts et al, 1986). Thus, rapid MTS-reactivity indicates location of a cysteine in the
water-accessible regions of a protein. A cysteine group facing the membrane or the
protein interior would not react or react poorly. The influence of MTS-reacted cysteines
on ligand binding is a measure of accessibility of a reporter cysteine in the ligand binding
pocket. The criterion for identifying an accessible reporter cysteine is the inhibition of
ligand binding due to the reaction with the MTS reagent. In addition, the residue is
identified as a part of the ligand binding pocket if the MTS reaction is retarded in the
presence of agonists or antagonists. If a position does not tolerate cysteine substitution
due to its role in protein stability, folding or ligand binding, its accessibility can be
inferred from neighboring reporters. Thus, exposure of site-directed cysteines, found in
the water-exposed surface and in the aqueous pockets, or channels, within the TM
proteins can be very rapidly and accurately measured by MTS reagents in situ, in the
native membrane environment, without purifying the protein to a homogenous
preparation.

Reporter cysteine accessibility mapping methodology was previously used to
determine activation-induced conformational changes in the TM helices of AT1R (Miura
et al, 2002, Miura et al, 2003, Boucard et al, 2003, Martin et al, 2007, Yasuda et al, 2008,
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Domazet et al, 2009). In these studies, the reaction rate and the degree of modification of
substituted cysteines by MTS reagents, measured by radioligand binding, was used to
infer dynamic changes in specific TM helices. However, the indirect measurement of
MTS-reactivity with a reporter cysteine has limitations. False negative results are
possible, since a reporter may be accessible, but ligand binding may not be inhibited by
its reaction with MTS reagent. If a residue is covered by ligand upon treatment, its
reactivity can not be determined.

We developed a new probing method which overcomes some of these limitations
in the current study. Using MTSEA-biotin (N-biotinylaminoethylmethanethiosulfonate)
reaction, followed by streptavidin-HRP detection (Fig. 3.6), we could directly analyze the
degree of modification of reporter cysteines. Figure 5.1 explains the principle behind the
MTSEA-biotin labeling strategy. This procedure can be performed both in the absence
and presence of the ligand. It allows us to get a direct readout for every position in
different ligand-bound states of the receptor.

In this chapter, the MTSEA-biotin accessibility of single cysteine mutants of
ECL2 was compared in different ligand-bound states; empty, agonist-bound and
antagonist-bound states. The reactivity of HA-CYS¯AT1R to MTSEA-biotin is
considered as baseline to identify a residue as accessible or inaccessible (Fig. 3.6). Any
significant measurement above the reactivity of HA-CYS¯AT1R indicates accessibility
of the particular reporter cysteine. The receptor topology was preserved during MTSEAbiotin reaction as closely as possible to the native state in the plasma membrane by using
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Figure 5.1. MTSEA-biotin labeling of accessible cysteine reporters. Schematic
explanation of principle behind MTSEA-biotin labeling strategy. MTSEA-biotin
preferentially reacts with water-accessible cysteines and does not react with buried or
disulfide bonded cysteines. The reaction of MTSEA-biotin with thiol group of an
accessible cysteine can be detected by Streptavidin-HRP.
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adherent cells rather than fractionated membranes. This analysis allowed us to deduce the
conformational changes of ECL2 associated with AT1R activation/inhibition.

5.2 Experimental Set Up for Accessibility Mapping
Intact COS1 cells expressing each of the reporter cysteine mutants were exposed
with 10 mM MTSEA-biotin for 30 min at room temperature (23 °C). We did not use >10
mM concentration for reasons of cost of the MTSEA-biotin reagent. Carrying out the
reaction at room temperature was necessary to minimize spontaneous and ligand-induced
receptor internalization. 20-30% of AT1R internalize spontaneously at 37 °C in 60 min.
Ang II induces internalization of >80% of AT1R at 37°C in 60 min. At room
temperature, Ang II-induced internalization of AT1R is <10% in 30 min. Under these
conditions, we were able to obtain optimal cysteine-biotinylation in AT1R without
affecting the integrity of cells (Fig. 5.2). As previously described in Section 3.4, the
modification levels of single cysteine mutants of ECL2 were determined by normalizing
the streptavidin-HRP signal of immunoprecipitated receptors to the HA signal. The
streptavidin-HRP signal of the HA-CYS¯AT1R was used as the control. The relative
MTSEA-biotin accessibility of a mutant was calculated as the ratio of streptavidin-HRP
signal for that mutant to the same signal for HA-CYS¯AT1R in the same experiment.
This control minimizes confounding factors which might influence the readout due to
different cell surface expression levels. Fully glycosylated monomeric receptor band was
monitored for the mapping studies. As seen in Table V.I, examination of monomeric
band yields more consistent results with lower standard error compared to multimeric
band. The overall accessibility pattern was same regardless of whether the monomeric or
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Figure 5.2. Optimization of MTSEA-biotin reaction conditions. A) Concentration
dependence of streptavidin-HRP signal. B) Time course analysis of Streptavidin-HRP
signal upon treatment with 10 mM MTSEA-biotin.
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Table V.I. Comparison of MTSEA-biotin reactivity of fully-glycosylated monomeric
receptor and multimeric forms of the receptor.

Mutants
HA-CYS¯AT1R
I172C
E173C
N174C
T175C
N176C
I177C
T178C
V179C
A181C
F182C
H183C
Y184C
E185C
S186C
R187C
N188C
S189C
T190C
L191C
P192C

41.9 kDa Monomeric form
Relative Accessibility
Mean
1.00
1.39
1.86
3.08
3.18
1.61
0.58
1.63
0.73
0.01
0.81
0.42
1.04
2.03
2.38
3.52
0.57
2.08
1.57
0.92
1.21
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S.E.M.
0.24
0.40
0.48
0.60
0.49
0.06
0.17
0.09
0.16
0.01
0.20
0.06
0.17
0.56
0.47
0.23
0.15
0.28
0.34
0.20
0.23

50-80 kDa Multimeric
Relative Accessibility
Mean
1.00
1.04
1.53
1.52
1.24
1.07
1.31
1.16
0.94
0.84
0.83
0.88
1.56
1.67
1.91
1.29
0.55
1.56
0.90
0.97
0.99

S.E.M.
0.28
0.24
0.79
1.21
0.97
0.35
0.38
0.26
0.10
0.21
0.42
0.32
1.04
0.62
1.46
0.92
0.13
1.43
0.17
0.75
0.96

the multimeric bands were analyzed.

The binding of agonist (Ang II) and antagonist (losartan) caused changes in the
reactivity of two representative cysteine reporters, replacing His183 and Glu185. The
H183C did not react in the absence of ligand (Fig. 5.3 A) but reacted very well in the Ang
II-bound state (Fig. 5.3 B). In contrast, Ang II binding rendered E185C less reactive,
although it was highly reactive in the absence of Ang II. In the presence of the antagonist
losartan, the reactivity of both cysteine reporters was reduced. These results provided the
first indication that the binding of agonists and antagonists induce distinct changes in the
conformation or position of ECL2 in AT1R. Differential labeling of a particular mutant
with and without agonist/antagonist suggests that the binding of ligand influences the
position/conformation of ECL2 and alters accessibility of the reporter.

In the empty-state, the observed MTSEA-biotin reactivity for H183C was
significantly lower compared to HA-CYS¯AT1R (Fig. 5.3 B), which has no free
cysteines. The reasons for lower reactivity of H183C and several other mutants are not
clear at this time. Theoretically, the MTSEA- biotin reaction for substituted cysteine
should be greater than or at least equal to HA-CYS¯AT1R. The observed discrepancy is
not correlated with the level of expression of H183C or other mutants and potential
masking of other cysteines in the basal conformation. Since Ang II or losartan binding
was able to change the H183C reactivity (Fig. 5.3 B), the substituted cysteine at this
position was acceptable as a sensor of local conformational change. We apply the same
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Figure

5.3.

MTSEA-biotin

accessibility

of

representative

mutants.

A)

Immunoprecipitated receptors were probed for HA (left) and Streptavidin-HRP (right) to
detect receptor expression and biotinylation levels respectively. The same blot was used
for probing with HA and Streptavidin-HRP. The blots for representative mutants H183C
and E185C are shown under three experimental conditions; in the absence of ligand
(upper), in the presence of 1 μM Ang II (middle) and in the presence of μM losartan
(lower). The fully glycosylated monomeric receptor band at 41.9 kDa was used for
determination of MTSEA-biotin accessibility. HA signal intensity and streptavidin-HRP
signal intensity of each sample was compared to the HA-CYS¯AT1R in the same gel as
indicated by numbers below the bands. The corresponding plots show the MTSEA-biotin
relative accessibility, which is the ratio of relative Streptavidin-HRP signal to relative HA
signal for particular sample. Relative MTSEA-biotin accessibility of each mutant was
compared to the HA-CYS¯AT1R in the same gel. Inset is the schematic representation of
reporter cysteines which point up when inaccessible and point down when accessible,
reacted with MTSEA-biotin (shown as -SR in red).
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consideration for other mutants.

5.3 Accessibility of ECL2 in the Absence of Ligand
The accessibility level of each single cysteine mutant was determined in
comparison to the HA-CYS¯AT1R control. The accessibility map of cysteine reporters in
ECL2 without ligand is shown in Figure 5.4 A. The mean ± S.E.M. observed for HACYS¯AT1R in nine independent experiments represents the streptavidin-HRP signal for
the receptor that lacks free cysteine residues. The red bar indicates the cut off value
below which the measurement is considered inaccessible. Significantly higher
streptavidin-HRP signal (mean ± S.E.M.) was observed for reporter cysteines residues in
two distinct regions of ECL2. The accessible N-terminal (Glu173, Asn174, Thr175, Asn176
and Thr178) and the C-terminal (Glu185, Ser186, Arg187, Ser189 and Thr190) regions were
separated by a region of low MTSEA-biotin reactivity. The inaccessible Ile177-Tyr184
segment contains at its center the highly conserved disulfide bond linking ECL2 to
TMIII. In addition, reporter cysteine residues at Ile172, Ile177, Asn188, Leu191 and Pro192
were also inaccessible. All of the mutants in which MTSEA-biotin labeling did not
increase, were expressed on the cell surface (Table IV.II) and efficiently
immunoprecipitated as shown by the HA blot, suggesting that the absence of signal was
due to the inaccessibility of the particular cysteine reporter, and not due to the lack of cell
surface expression. Unlabeled receptors with reduced cell surface expression levels
(I177C, P192C) were still present at sufficient quantity to yield accessibility signal, as
seen upon ligand exposure (see section 4.3).
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Figure 5.4. MTSEA-biotin accessibility maps of ECL2 single cysteine mutants. The
MTSEA-biotin relative accessibility of mutants are expressed as mean ± S.E.M., n=3.
Red line shown on graph designates the significance cut off (S.E.M. of HA-CYS¯AT1R
accessibility, n=9) that determines the accessibility of mutants. Mutants with significantly
higher accessibility compared to HA-CYS¯AT1R are indicated with red asterisk. The
conserved Cys180 residue is marked by gold star. A) MTSEA-biotin accessibility map of
ECL2 mutants in the absence of ligand. The autoantibody binding epitope sequences are
indicated in dark red. B) MTSEA-biotin accessibility map of ECL2 mutants in the
presence of AngII. C) MTSEA-biotin accessibility map of ECL2 in the presence of
losartan.

100

101

5.4 Accessibility of ECL2 Upon Ang II Binding
Surprisingly, Ang II treatment prior to MTSEA-biotin reaction significantly
reduced the overall accessibility of ECL2 (Fig. 5.4 B). Residues Glu173, Asn174, Thr175,
Asn176 and Thr178, Glu185, Ser186, Arg187 and Thr190 which were found to be highly
reactive in the absence of ligand did not react in the presence of Ang II. The protection of
residues by Ang II implies two possibilities, either that Ang II masked these residues
directly or that ECL2 undergoes an Ang II-dependent conformational change. The pattern
of accessibility throughout the ECL2 residues clearly indicates that blocks of residues
show similar accessibility patterns rather than individual ones. Decreased accessibility of
consecutive residues of ECL2 in two segments rather than individual residues supports
the idea that Ang II induces conformational rearrangement of ECL2. Ang II binding
increased the accessibility of Ala181, Phe182 and His183, which are immediately C-terminal
to the disulfide bonded Cys180. Thus, the Ang II-induced change is consistent with
increase in local conformational entropy involving the disulfide bond.

5.5 Accessibility of ECL2 Upon Losartan Binding
The presence of AT1R-selective antagonist, losartan, during the MTSEA-biotin
labeling (Fig. 5.4 C) also decreased the overall reactivity of ECL2 similar to Ang IIbound state. These accessibility changes in the presence of antagonist are similar to that
observed in rhodopsin (Palczewski et al, 2000, Ahuja et al, 2009) and dopamine receptor
(Shi et al, 2004) where ECL2 forms a cap over the inhibitor binding site.
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However, losartan binding increased the reactivity of residues in the Asn176-Val179
region, which are immediately N-terminal to the disulfide bonded Cys180. Thus, losartan
binding induced flexibility on the other side of the disulfide bond compared to Ang II
bound-state. Thus, conformational changes induced near the disulfide bond upon binding
of the agonist are different from those induced by binding of the antagonist. These results
suggest that ECL2 adopts different conformations in Ang II- and losartan-bound states.

5.6 Rate of Change in MTSEA-biotin Accessibility
The observation that the accessibility of residues on either side of the disulfide
bond-tether of ECL2 changes upon ligand binding raised an important question: Do the
induced conformational changes indicate a flexible or rigid-body motion of ECL2? Does
the conformation of ECL2 change as a single entity or do different segments (residues) of
ECL2 have different rates of accessibility changes?

We determined the rate of accessibility change for two representative reporter
cysteines in ECL2, on each side of the disulfide-tether. The reactivity of MTSEA-biotin
was measured following 0 min, 2 min, 5 min and 10 min treatment with Ang II. The
accessibility of N174C reporter decreased in the presence of Ang II, with a slope of 0.298
which suggested a gradual conformational change for this residue (Fig. 5.5 A). On the
other hand, the accessibility of F182C reporter increased in the presence of Ang II, with a
slope of 0.058. The slower rate observed for Phe182 residue compared to Asn174 might be
due to the fact that Phe182 residue is closer to the disulfide bond which might have
restricted its flexibility to some extent compared to a residue far from the disulfide bond
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restriction. The result indicates that the two segments in ECL2 have different rates of
accessibility changes (Fig. 5.5 B). This observation suggested that ECL2 does not change
its conformation as a single entity; instead, two regions undergo conformational changes
independently from each other.

ECL2 is highly accessible in the absence of any ligand. Agonist and antagonist
binding differentially alters the accessibility of ECL2 leading to distinct conformations in
two different ligand-bound states. The data suggests that ECL2 is a flexible region as
predicted by theoretical models. Tethering ECL2 to TMIII via the conserved disulfide
bond is an important structural constraint, giving different flexibility to two segments of
ECL2, which allows ECL2 to follow different folding depending upon the nature of the
ligand. A ligand-specific conformational change of ECL2 may be associated with the
activation/inhibition of AT1R.
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Figure 5.5. Rate of change in MTSEA-biotin accessibility for representative
mutants. A) Rate of change in MTSEA-biotin accessibility for N174C mutant.
Experiment was performed by treating cells with 1µM Ang II for 0 min, 2 min, 5 min and
10 min. The relative accessibility to 20 mM MTSEA-biotin was measured as described
before. Inset shows the linear trend line and the equation. B) Rate of change in MTSEAbiotin accessibility for F182C mutant. Inset shows the trend line and the equation.
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CHAPTER VI
INSIGHTS FROM MOLECULAR DYNAMICS (MD) SIMULATIONS

6.1 Introduction
As a computational approach, molecular dynamics (MD) simulations provide
insights into the dynamic nature of biological molecules and their inherent motion as a
function of time. It helps the interpretation of experimental data. We performed MD
simulations using the accessibility constraints determined by MTSEA-biotin labeling
(Fig. 5.3) to predict the conformation of the ECL2. MD simulations were performed
using model structures of AT1R (PDB ID: 2AC6) and AT1R with Ang II (PDB ID:
2AH3) as explained in Figure 2.10. The ECL2 simulation in the presence of losartan was
performed on a de novo AT1R model docked with losartan. Together, these studies
provide a greater insight into the functional role of dynamic motions in ECL2 and
improve our understanding of AT1R interaction with Ang II, losartan and autoantibodies.
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6.2 Overall Approach
MD simulation on empty, Ang II-bound and losartan-bound models was
performed as explained in Figure 2.10. In each instance, 100 frames were obtained at the
end of 14 ns simulation. To illustrate the strategy, all 100 frames for the empty state of
the receptor are shown in Figure 6.1 as an example. The overall backbone conformation
of ECL2 in each frame is examined for conformity with the experimental results obtained
using MTSEA-biotin accessibility mapping of the ECL2 in the empty state of the
receptor. Among several frames which displayed an ECL2 conformation concordant with
the experimental data, we chose the frame number 1 (Figure 6.2 A) for the empty state of
the receptor. When the side chains of the ECL2 region were added (Figure 6.2 B) and
energy minimization was carried out, the final orientation of every side-chain matched
the accessibility data for this frame. The same analysis was done for the Ang II- and
losartan-bound states.

6.3 MD Simulation of ECL2 in the Absence of Ligand
The MD simulation in the absence of any ligand indicated that ECL2
conformation is open toward the extracellular space (Fig. 6.2). The accessible residues on
the N-terminal (Glu173, Asn174, Thr175, Asn176 and Thr178) and the C-terminal (Glu185,
Ser186, Arg187, Ser189 and Thr190) regions of the ECL2 are shown in red color. The Val179
to Tyr184 region harboring the conserved disulfide bond is deeper and more restricted than
the N-terminal and C-terminal regions of the loop. Disulfide bonded cysteines, Cys101 and
Cys180, are shown in yellow. The access to the ligand-binding pocket is wider near TMVTMVII, providing an open aqueous channel (see Chapter VII for discussion).
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Figure 6.1. MD simulation of the ECL2 in the empty state of the receptor. A) The
100 frames obtained from the MD simulation analysis of ECL2 in the empty state of the
AT1R following 1000 steps of energy minimization using the backbone structure of
AT1R model. (PDB ID: 2AC6) The ECL2 is shown in red. B) Superimposition of 100
frames from the MD simulation analysis of ECL2 in the empty state of the AT1R.
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A)
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B)
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Figure 6.2. The frame # 1 chosen for further analysis. A) Among the 100 frames, the
frame #1 was chosen since the ECL2 conformation is consistent with the experimental
results found by MTSEA-biotin accessibility mapping of ECL2 in the empty state of the
AT1R. B) The side chains were then added to the ECL2 backbone. The disulfide bonded
cysteines are shown in yellow.

A

B
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6.4 MD Simulation of ECL2 in the Presence of Ang II
The MD simulation in the presence of Ang II depicts ECL2 forming a tightly
packed lid against bound Ang II, which is shown in magenta in Figure 6.3. The accessible
residues Ala181, Phe182 and His183 which are immediately C-terminal to the disulfide bond
are shown in red.

6.5 MD Simulation of ECL2 in the Presence of Losartan
The MD simulation in the presence of losartan which is shown in blue in Figure
6.4 also depicts a lid conformation of ECL2 similar to Ang II bound state of the receptor.
The accessible residues, Asn176-Val179, which are immediately N-terminal to the highly
conserved disulfide bond, are shown in red color. These results suggest that ECL2 adopts
lid conformations in both Ang II- and losartan- bound states, but in a distinct orientation.
Varying positions of the disulfide bond and the neighboring accessible residues in Ang
II- and losartan-bound conformations of ECL2 indicates flexibility of the region that is
normally thought to be constrained because of the disulfide bond.

6.6 Analysis of Hydrogen Bonding Networks
The overall decrease of ECL2 accessibility in the Ang II- and losartan-bound
states compared to the empty state indicates that ECL2 conformation changes upon
receptor activation. We used inaccessible residues as constraints to perform molecular
dynamic simulation to gain insights on ECL2 conformational rearrangements. We
analyzed the hydrogen bonding of the inaccessible residues in the empty, Ang II-bound,
and losartan-bound states of the AT1R. To assign the rearrangement of hydrogen bonding

112

Figure 6.3. The frame # 48 chosen for further analysis. A) Among the 100 frames, the
frame #48 was chosen since the ECL2 conformation is consistent with the experimental
results found by MTSEA-biotin accessibility mapping of ECL2 in the Ang II-bound state
of the AT1R. B) The side chains were then added to the ECL2 backbone. The disulfide
bonded cysteines are shown in yellow. Ang II is shown in magenta.

A

B
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Figure 6.4. The frame # 39 chosen for further analysis. A) Among the 100 frames, the
frame # 39 was chosen since the ECL2 conformation is consistent with the experimental
results found by MTSEA-biotin accessibility mapping of ECL2 in the losartan-bound
state of the AT1R. B) The side chains were then added to the ECL2 backbone. The
disulfide bonded cysteines are shown in yellow. Losartan is shown in blue.
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network in each receptor state, we simulated 3.2 Å hydrogen bond contacts of
inaccessible ECL2 residues. In the empty state, ten inaccessible residues (Ile172, Ile177,
Val179, Ala181, Phe182, His183, Tyr184, Asn188, Leu191 and Pro192) are involved in extensive
interaction with TMII, TMIII, TMIV and TMV and ECL3 (red) (Fig. 6.5). A list of
interactions in the absence of ligand is given in Table VI.I.

In the Ang II-bound state, sixteen residues inaccessible to MTSEA-biotin (Ile172,
Glu173, Asn174, Thr175, Asn176 Ile177, Thr178, Val179, Tyr184, Glu185, Ser186, Arg187, Asn188,
Thr190, Leu191 and Pro192) increase intra-molecular contacts of ECL2 with TMI, TMII,
TMIII, TMIV, TMV, TMVII and extra-cellular segments, N-terminal tail, ECL1 and
ECL3 (red, Fig. 6.6). Two intermolecular hydrogen bonding networks; the first (green)
between Ang II and TM-helices and the second (blue) between Ang II and ECL2
highlights the major difference between basal and active states of AT1R. A list of
interactions in the presence of Ang II is given in Table VI.II A and B. The N-terminal
residues of Ang II are involved in interactions with TMIII and TMVII (green). The Cterminal residues of Ang II are involved in interactions with N-terminal residues of ECL2
(blue).

The intra-molecular hydrogen bonding network in the presence of losartan is even
more extensive including interactions with all TM helices (except TMI), N-terminal tail,
ECL1 and ECL3, however these contacts are distinct compared to Ang II-bound state.
The rearrangement of hydrogen bonding network in the inhibited receptor state upon
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Figure 6.5. Hydrogen bonding network of ECL2 in the absence of ligand. A)
Predicted intramolecular interactions of inaccessible residues of ECL2 with the TM
helices in the absence of ligand are shown in red. TM helices are depicted as helical
wheel

diagram

generated

using

Helical

Wheel

Projections

(http://rzlab.ucr.edu/scripts/wheel/). Loop and extracellular residues are highlighted in
yellow. B) Cartoon depiction of ECL2 interactions with TMD.
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Table VI.I. Predicted interactions of inaccessible ECL2 residues with transmembrane residues in
the absence of ligand.

ECL2
I172
I177
V179
C180
A181
F182
H183
Y184
N188
L191
P192

TM interactions
Y170
T80, T88, L100, L81
F171, A104, C101, S105
V169, F171, Y170, Disulfide bond with C101
V169, N168
R167, H272, I271
L112, N168, V270, I271, H272, D273, C274
S109, V108, I271, C274
S107, K199, H272, D273
H166, I165, V164, I193, G196, L195
G194, L195
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Figure 6.6 Hydrogen bonding network of ECL2 in the presence of Ang II. A)
Predicted intramolecular interactions of inaccessible residues of ECL2 with the TM
helices in the presence of Ang II are shown in red. Two intermolecular hydrogen bonding
network between Ang II and ECL2 (blue) and between Ang II and TM helices (green) are
also shown. Loop and extracellular residues are highlighted in yellow. B) Cartoon
depiction of ECL2 interactions with TMD (red), ECL2 interaction with Ang II (blue) and
Ang II interactions with TMD (green). Ang II is shown in yellow. Three different
hydrogen bonding networks stabilize the lid conformation.
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Table VI.II
A. Predicted interactions of inaccessible ECL2 residues with transmembrane residues in the
presence of Ang II.

ECL2
I172
E173
N174
T175
N176
I177
T178
V179
C180
Y184
E185
S186
R187
N188
T190
L191
P192

TM interactions
L100, Y170, W94, R93, C101
A89, Y92, R93
A104, Y170, F171, T88, C101
A89, A85, P82, T88, L81
I32, Y35, F31
I288, Y292

Y170, Disulfide bond with C101
C274, H272, I271
Y170, F171, R13, I14
V169, R13, I14
F171, R13, K275, C274
A7, K12
I165, R167, V164, G196, L195, I271
G196, G194

B. Predicted interactions of Ang II with transmembrane residues and ECL2.

Ang II
D1
R2
V3
Y4
I5
H6
P7
F8

TM interactions
ECL2 interactions
L112
N111,A114,S115
N294,N295
I290,A291,Y292,F293,N294,N295
S107,V108,S109
E173
I177,T178,V179
I172,T178
S109,Y113
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losartan binding is shown in detail in Figure 6.7. The intermolecular hydrogen bonding
network between TM helices and losartan (green) is less extensive than that between
losartan and ECL2 (blue). A list of interactions in the presence of losartan is given in
Table VI.III A and B.

Together, molecular dynamic simulation studies predict a flaccid ECL2
conformation in the empty state. The ECL2 becomes more strongly hydrogen bonded in
the ligand-bound state. Extensive intra-molecular hydrogen bonding network of ECL2
with the TM helices, ECL1, ECL3 and N-terminal tail stabilizes a compact ‘lid’ like
structure in both Ang II- and losartan-bound states. Two intermolecular hydrogen
bonding networks between Ang II and TM helices and Ang II and ECL2 stabilize the
agonist bound to the receptor. Individual contacts for the same ECL2 residues differ in
agonist- and antagonist-bound states. Cooperatively, these hydrogen bonding networks
may account for the experimentally found inaccessibility of ECL2 in the ligand-bound
state and govern the high-affinity of AT1R towards Ang II and losartan and their rapid
binding followed by slow dissociation (see chapter VI for discussion). Leaning of Ang IIbound ECL2 towards one set of residues and losartan-bound ECL2 towards a different set
appears to contribute respectively to receptor activation and inhibition.
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Figure 6.7 Hydrogen bonding network of ECL2 in the presence of losartan. A)
Predicted intramolecular interactions of inaccessible residues of ECL2 with the TM
helices in the presence of losartan are shown in red. Two intermolecular hydrogen
bonding network between losartan and ECL2 (blue) and between losartan and TM helices
(green) are also shown. Loop and extracellular residues are highlighted in yellow. 1;
imidazole ring, 2; phenyl ring 1, 3; phenyl ring 2, 4; tetrazole ring. B) Cartoon depiction
of ECL2 interactions with TMD (red), ECL2 interaction with losartan (blue) and losartan
interactions with TMD (green). Losartan is shown in cyan. Three different hydrogen
bonding networks stabilize the lid conformation.
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Table VI.III
A. Predicted interactions of inaccessible ECL2 residues with transmembrane residues in the
presence of losartan.

ECL2
I172
E173
N174
T175
C180
A181
F182
H183
Y184
E185
S186
R187
N188
T190
L191
P192

TM interactions
R13, I14, D17, D16, W84, W94, F96, L100
K12, R13, Q15, Y170, F171, A104, S107, V108, C101
P95, L81, P82
Y170, W94, A85
Y170, F171, Disulfide bond with C101
Y170
P285,M284
S107,I271,V270, T287,M284, S109
S160, A106, H272, F259
H166, V164, V169
Y170, F171,V169
F171, V169, N168, H166, R167, Y170, F259
S109, V108, S105
V270, L195, G196
H272, L197, G196
L195, G196

B. Predicted interactions of losartan with transmembrane residues and ECL2. 1; imidazole ring, 2;
phenyl ring-1, 3; phenyl ring-2, 4; tetrazole ring.

Losartan
1
2
3
4

TMD interactions
H256,I288
H256,T260
Y113,K199,N200
H256,Y113,Q257

ECL2 interactions
A181,F182,H183,Y184,S186, R187,N188
A181,H183,Y184, S186, N188,S189,T190
S189,T190
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CHAPTER VII
DISCUSSION

7.1 The Implications of Ligand Induced Conformational Change of ECL2
Results presented here shed new light on ligand-specific structural dynamics of
ECL2 in AT1R. In many peptide hormone GPCRs including AT1R, ECL2 directly
interacts with agonists and is also a target of auto-antibodies. Hence the ligand-specific
conformational dynamics of ECL2 in AT1R we describe here are insightful.

An open conformation of ECL2 has been indicated by the accessibility
measurements and molecular dynamics simulation of ECL2 in the empty state of the
AT1R (Fig. 7.1 A). The open conformation of ECL2 may facilitate capture of ligands in
AT1R by providing an aqueous channel to facilitate ligand entry and exit from the
binding pocket in milliseconds (Bourne & Meng, 2000, Cherezov et al, 2007, Warne et
al, 2008, Jaakola et al, 2008). As ligands enter the binding pocket through this aqueous
channel, they may have transient interactions with the ECL2, an interpretation which is
consistent with previous biochemical studies. Photoaffinity cross-linking studies have
shown that Val3 in Ang II is cross-linked with Ile172 in ECL2 (Perodin et al, 2002).
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Figure 7.1. Molecular dynamics simulation of ECL2. A) Molecular dynamics
simulation of ECL2 in the absence of ligand. TMI, TMII, TMIII, TMVI and TMV are
shown in cartoon model. The ECL2 residues and side chains are shown in stick and
surface model. The accessible residues are shown in red. The disulfide bonded cysteines
Cys101 (TMIII) and Cys180 (ECL2) are shaded in yellow. B) Molecular dynamics
simulation of ECL2 in the presence of Ang II. Ang II is shown as magenta stick. The
accessible residues are shown in red. C) Molecular dynamics simulation of ECL2 in the
presence of losartan. Losartan is shown as blue stick. The accessible residues are shown
in red. D) Zoomed view of ECL2 simulations in the empty, Ang II-bound and losartanbound states of the receptor.
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Site-directed mutagenesis studies have shown that Ile172 and His183 in ECL2 specifically
interact with Val3 and Asp1 side chains in Ang II, respectively (Feng et al, 1995, Boucard
et al, 2000).

The accessibility measurements and molecular dynamics simulation of ECL2
indicated a “lid” conformation of ECL2 in the Ang II-bound state of the AT1R (Fig. 7.1
B). Mutagenesis studies established direct interactions between TM helices II, III, V, VI
& VII and Ang II. Photoaffinity cross-linking studies have shown that Phe293/Asn294 in
TMVII interact with Phe8 of Ang II (Perodin et al, 2002). A molecular model of AT1R
predicted that ligands bind in the TM domain ≈ 25 Å away from the membrane border
(Gogonea et al, 2006). The model suggests that the N-terminal part of ECL2 dips into the
binding pocket reaching the bound Ang II (Gogonea et al, 2006). Binding of Ang II may
induce folding of ECL2 to an elaborate ‘lid’ conformation similar to that seen in the case
of bovine rhodopsin (Fig. 5.3 B). This lid may interact with additional elements of the
receptor's extracellular domain, i.e. ECL1, ECL3 and the NT. Thus, the ligand-induced
folding of ECL2 requires considerable rearrangement of the hydrogen bonding networks
in AT1R (Fig. 7.2).

A similar “lid” conformation of ECL2 in the losartan-bound state of the AT1R is
indicated by the accessibility measurements and molecular dynamics simulation of ECL2
(Fig. 7.1 C). Mutagenesis, photoaffinity cross-linking and modeling studies (Boucard et
al, 2000, Yamano et al, 1992, Noda et al, 1995, Schambye et al, 1994, Ji et al, 1994,

129

Figure 7.2. Predicted hydrogen bonding network formed by inaccessible residues of
ECL2. The ECL2 is highlighted in dark grey. A) Intramolecular interactions of ECL2
with the TM helices (red) in the absence of ligand. B) Intra-molecular interactions of
ECL2 with the TM helices (red) in the presence of Ang II. Ang II is shown in yellow
spheres. Two intermolecular hydrogen bonding network between Ang II and ECL2 (blue)
and between Ang II and TM helices (green) are also shown. C) Intra-molecular
interactions of ECL2 with the TM helices (red) in the presence of losartan. Losartan is
shown in cyan spheres. Two intermolecular hydrogen bonding network between losartan
and ECL2 (blue) and between losartan and TM helices (green) are also shown.
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Nouet et al, 2000) show that losartan competitively occupies the Ang II binding site,
implying that conformational rearrangement induced by losartan in another part of the
receptor is not the cause of reporter Cys reactivity in ECL2. Molecular modeling studies
show that the only mechanism for simultaneous ECL2 and TM domain interaction with
losartan would be through folding of ECL2 into the pocket within the TM domain.
Molecular dynamic simulation studies shown in Figure 5.3 C provide strong support for
ECL2 forming a lid over losartan bound to the TM domain. Simulated interactions
include direct contact between ECL2 and losartan and between ECL2 and TM-domain as
well as ECL2 and other EC loops (Fig. 6.7).

7.2 The Potential Role of Conserved Disulfide Bond
Ligand-specific folding of ECL2 appears to induce specific perturbation around
the disulfide bond, which may play a critical role in the inhibition and activation of the
receptor. A distinct pattern of accessibility changes caused by losartan on the N-terminal
side of the disulfide bond and by Ang II on the C-terminal side of the disulfide bond
suggest that type of constraint experienced by the disulfide bond plays a critical role in
the inhibition and activation of TM signaling, respectively.

The N-terminal residues in Ang II interact with ECL2 and the C-terminus with the
receptor’s inter-helical crevice, leading Ang II to fold into a ‘C’ shape, a conformation
predicted in many studies (Marshall et al, 1974, Samanen et al, 1994, Garcia et al, 1992,
Nikiforovich et al, 1994). Dynamics of ECL2 might be critical in the Ang II binding
process, since three N-terminal residues in Ang II sequentially interact with Ile172, His183
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in ECL2 and Asp281 in ECL3/TMVII, while the Ang II C-terminus inserts into receptor’s
inter-helical crevice. The Ang II docking process may be completed, upon folding of the
peptide ligand to a ‘C’ shape. We propose that ligand binding in AT1R leads to specific
reorganization of the hydrogen bond network formed primarily with residues on ECL2,
which is then coupled to the movements of TM helices involving the Cys101–Cys180 bond.

The ECL2 length (27±13) is conserved in the GPCR family (Karnik et al, 2003),
but the frequency of activating mutations targeting this region is lower than in the TM
helices. Individual mutations in a flexible region of receptors may not relax the constraint
for activation as readily as single residue mutations in TM helices. What is the
significance of ligand-specific conformation of ECL2 in the receptor activation process?
One possibility is that in the ligand bound state, the ECL2 interacts with multiple TM
helices, which enables ECL2 to integrate conformational cues originating at multiple
contacts between ligand and the receptor. In fact, the hydrogen bonding network analysis
of ECL2 (Fig. 6.6) has shown that there is a considerable rearrangement of hydrogen
bonding, increasing the number of contacts between ECL2 and TM domain. The disulfide
bond located in the middle of ECL2 may be required for transmitting the conformation to
TMIII. Conservation of the disulfide bond in >90% GPCR may indicate a general role for
this bond in efficiently coupling ligand binding to GPCR activation.

7.3 The Structural Basis for Binding of Autoantibodies
The open conformation of the ECL2 in the empty receptor is independently
supported by autoantibody epitope mapping studies in human AT1R (Liao et al, 2002,

132

Dragun et al, 2005, Zhou et al, 2008). Autoantibodies directed towards ECL2 in many
GPCRs mimic the action of agonists, but their mechanism of action is unclear.
Circulating autoantibodies recognize the readily accessible Ile172–Thr178 and Glu185–
Thr190 segments. For instance, agonistic autoantibodies from preeclampsia patients bind
to the epitope ‘AFHYESQ’ (Zhou et al, 2008), and agonistic autoantibodies from patients
with malignant hypertension and refractory, vascular allograft rejection bind to epitopes
‘ENTNIT’ and ‘AFHYESQ’ in ECL2 (Liao et al, 2002, Dragun et al, 2005). It is
interesting to note that the antigenic epitopes (dark red in Fig. 5.3 A) are interrupted by
the Val179–Tyr184 region adjoining the disulfide bond that was found to be inaccessible by
RCAM. Our analysis suggests that these autoantibodies can capture the accessible region
and losartan could mask these epitopes to prevent such binding. Losartan binding, which
masks epitopes, is known to protect patients harboring autoantibodies.

In many other GPCRs the auto-antibodies directed towards ECL2 may also
modulate the conformation of the EC-domain (Lebesgue et al, 1998, Wang et al, 2000).
Autoantibodies directed against ECL2 regions were discovered in several human
pathologies involving the muscarinic receptors, α1 and β1 adrenergic receptors and the
bradykinin B2 receptor. In a more general sense, the conformational dynamics of ECL2
may regulate the fundamental process of autoantibody-mediated activation and
pathophysiological process involving GPCRs. Conformational display of epitopes in
ECL2 may be the basis for allosteric activation of GPCRs by autoantibodies.
Autoantibody binding to ECL2-epitopes may exert tension on the disulfide bond to

133

activate the AT1R directly or may open the entrance channel for circulating Ang II. Our
findings might offer strategies for improved therapies.

7.4 A Predicted Ang II-analogous pharmacophore in ECL2
Of great interest, out of ten inaccessible residues in the empty state of the
receptor, seven residues are similar to the residues in Ang II (Fig. 7.3), but their order is
not the same as in Ang II. We speculate that the inaccessible residues of ECL2 may
actually regulate low basal activity of ligand free receptor by presenting an Ang IIanalogous pharmacophore hidden within ECL2. Our RCAM analysis uncovered
existence of this hidden pharmacophore, a set of structural features in ECL2 that might
have a pharmacological effect on the receptor. Effect of the hidden pharmacophore in the
empty receptor may be inhibitory. The hydrogen bonding network analysis of ECL2 in
the absence of ligand (Fig. 6.5 A) has shown that some of the ECL2 interacting residues
in TM domain are within the 3.2 Å of Ang II interacting residues (e. g. Lys199 is an Ang
II binding residue). When the primary sequence of Ang II is scrambled, an inhibitory
pharmacophore is generated as shown earlier (Marshall et al, 1974, Bumpus et al, 1977,
Samanen et al, 1994, Miura et al, 1999). For instance exchanging residues at 4th, 6th and
8th positions in Ang II converts the agonist to an antagonist, and lowers affinity for
AT1R. Whether the predicted Ang II-analogous pharmacophore in ECL2 works like an
extremely weak agonist or antagonist needs further study.
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Figure 7.3. Ang II analogous ECL2 Pharmacophore. *The inaccessible residues of ECL2 in
the empty-state which are similar to Ang II residues are shown. Three Ang II analogs with
different properties are also shown where the scrambled residues are indicated in bold italic.
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7.5 The ECL2 of AT1R in context of GPCRs
Previous studies in different GPCRs suggested that ECL2 is important for inactive
receptor conformation and participates in ligand binding. Therefore, we evaluated the
dynamic role of ECL2 in AT1R as the basis for complex functions attributed to it. Our
RCAM results indicated that the ECL2 reacts with MTSEA-biotin with exception of the
conserved disulfide bonded region. Binding of an agonist or antagonist limited solvent
accessibility of most residues in ECL2, but the accessible residues differ in the presence
of agonist and antagonist. These findings can be reconciled assuming that the ECL2
undergoes specific ligand-induced conformational changes as a consequence of ligandreceptor interaction. The conformational changes associated with TM and cytoplasmic
domains of GPCRs during activation are conserved. We propose that specific kinetic and
thermodynamic prerequisite for ligand and autoantibody recognition are achieved
through conformational dynamics of ECL2.

Structural changes in the ECL2 of GPCRs upon activation have been
characterized for several GPCRs including rhodopsin and β-adrenergic receptors. In
bovine rhodopsin, a compact ‘lid’ conformation of the extracellular domain which
interacts with the inverse agonist form of the chromophore is documented (Bourne and
Meng, 20005, Massotte et al, 2005, Palczewski et al, 2000, Park et al, 2008, Ahuja et al,
2009). A less compact ‘lid’ conformation is maintained in opsin with an aqueous channel
opening near the extracellular ends of TMV-TMVII and ECL3 (Park et al, 2008). NMR
studies in light activated rhodopsin have shown the movement of ECL2 away from the
activating ligand, all-trans-retinal. The ECL2 sequence of AT1R and rhodopsin share 11
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of 21 residues (Fig. 7.4) and the predicted structures of ECL2 are ideally positioned to
form multiple interactions with the bound ligand and other segments of the receptor
(Gogonea et al, 2006). The ECL2 sequence of AT1R shows high propensity to form a βhairpin structure and a salt-bridge similar to rhodopsin. Direct interaction of Ang II
possibly induces folding of ECL2 to a ‘lid’ conformation (Fig. 5.3 B), which is different
when compared to the movement of ECL2 away from the activating ligand, all-transretinal in light-activated rhodopsin (Ahuja et al, 2009). Considering the conformational
changes in the TM domain, movements of TMIII, TMV, TMVI and TMVII have been
shown to be critical for activation of both rhodopsin and AT1R.

Similar extracellular lids blocking the exit of bound inhibitory ligands are not
found in the subsequently solved GPCR structures of β-adrenergic and adenosine
receptors. Although tethered to TMIII, the ECL2 in these GPCRs is stabilized outside the
ligand pocket by additional disulfide bonds (Cherezov et al, 2007, Warne et al, 2008,
Jaakola et al, 2008). In the crystal structure of the β-adrenergic and adenosine receptors,
ECL2 is not as extensively associated with the ligand binding pocket, leading to the
speculation that absence of extracellular lid facilitates ligands’ entry and exit through the
binding pocket in milliseconds. In rhodopsin-like peptide hormone receptors,
significantly greater involvement of the ECLs in agonist interaction is documented
(Karnik et al, 2003). What is the effect of reversible binding of diffusible ligands on the
ECL2 conformation of peptide GPCRs? A recent solid-state NMR study on β2adrenergic receptor has shown that agonists induce a conformational change in ECL2 that
differs from those induced by inverse agonists and an inward movement of ECL2 is
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Figure 7.4. Alignment of ECL2 of AT1R with the ECL2 sequences of GPCRs for which
crystal structures are available. The conserved cysteine is indicated by asterisk. The cysteines
which are involved in disulfide bond formation in each GPCR is boxed in gold (1-7). The
alignment was generated by using ClustalW2 (http://www.ebi.ac.uk/clustalw/).
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associated with the active state of the β2-adrenergic receptor (Bokoch et al, 2010).

In all five main human GPCR families (rhodopsin, glutamate, secretin, adhesion
and frizzled/taste2), mutations targeting ECLs impair ligand dependent activation, also
suggests a conserved function of the EC-domain throughout the GPCR superfamily
(Karnik et al, 2003). Thus, the dynamic conformational changes in the ECL2 may be
critical for the activation mechanism of the GPCRs. Mutations on the ECL2 led to
constitutive activation in GPCRs such as TSH receptor and C5A receptor (Duprez et al,
1997, Klco et al, 2005). ECL2 is a negative regulator of C5a receptor activation as
discovered by genetic analysis. A similar role in stabilizing the inactive state in other
GPCRs is proposed. In our study, none of the mutations caused constitutive activation
and a previous genetic analysis also did not find mutations in ECL2 that cause activation
of AT1R. ECL2 possibly serves an essential function in protein folding and maintaining
the folded-state of the AT1R as indicated by I177C and V179C mutations. The
susceptibility of folded AT1R to reducing agents is due to breaking the Cys101–Cys180
disulfide linkage with TMIII (Ohyama et al, 1995, Feng et al, 2000).

A rhodopsin-like ‘lid’ formed by ECL2 in the losartan-bound state is quite similar
to the proposed arrangement of ECL2 in the D2 dopamine receptor in the antagonist
bound state (Shi & Javitch, 2004). In other GPCRs the conformation of ECL2 in the
presence of agonist is not reported. Similar conformational changes are likely in other
GPCRs, where a direct role of ECL2 in ligand specificity is documented (Zhao et al,
1996, Duprez et al, 1997, Banares et al, 2005).
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Current ideas about how an extracellular lid may limit the access of ligands to
cognate GPCRs are based on extrapolation from elegant dynamic and structural studies
on bovine rhodopsin (Palczewski et al, 2000, Park et al, 2008, Ahuja et al, 2009). Our
analysis allows us to reach a different conclusion, that a ‘lid’ conformation is induced in
AT1R upon binding of both agonists and antagonists.

7.6 Final Remarks
The results of the current work provide explanation for several previous
observations that remained unanswered. The open conformation of ECL2 provides an
aqueous channel that facilitates access of ligands to the ligand binding pocket deep in the
TM domain. As ligands enter the binding pocket through this aqueous channel, they may
have primary interactions with the ECL2, an interpretation which is consistent with
previous mutagenesis and cross-linking studies. The N-terminal residues in Ang II
sequentially interact with Ile172 and His183 in ECL2, while the C-terminal residues in Ang
II inserts into the binding crevice, interacting with TM residues (Gogonea et al, 2006).
Photoaffinity cross-linking studies have shown that Val3 in Ang II is cross-linked with
Ile172 in ECL2 (Perodin et al, 2002) and Phe293/Asn294 in TMVII interact with Phe8 of
Ang II (Perodin et al, 2002), leading Ang II to fold into a ‘C’ shape, a conformation
predicted in NMR studies (Marshall et al, 1974, Samanen et al, 1994, Garcia et al, 1992,
Nikiforovich et al, 1994). The mechanism for simultaneous interaction of Ang II with
ECL2 and TM domain can only be explained through folding of ECL2 into the pocket
within the TM domain, as we have shown here. The Ang II docking process may be
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achieved by specific rearrangement of the hydrogen bond network of ECL2, which is
then coupled to the movements of TM helices involving the conserved disulfide bond.

The open conformation of the ECL2 in the empty receptor is independently
supported by autoantibody epitope mapping studies in human AT1R (Liao et al, 2002,
Dragun et al, 2005, Zhou et al, 2008). Autoantibodies directed towards ECL2 of AT1R
recognize the Ile172–Thr178 and Glu185–Thr190 segments, which are found to be readily
accessible in our results. Our analysis suggests that these autoantibodies can capture the
accessible region on the ECL2. It has been shown that, losartan binding could mask these
epitopes to prevent autoantibody binding and protect patients harboring autoantibodies.
The lid conformation of ECL2 induced by losartan suggests that the epitope regions are
rendered inaccessible to autoantibodies, preventing their interaction with the AT1R.

Transient formation of an EC-lid is most likely very important in GPCRs for
blocking rapid exit of the ligand from the pocket. Their ligands bind to the pocket rapidly
and leave the binding pocket at a much slower rate. For example, the dissociation rate (ka)

is five times larger than the association rate (ka) of both Ang II and losartan for AT1R

(Timmermans et al, 1993, Ojima et al, 1997). A transiently formed ‘lid’ can prevent the
ligands from leaving the pocket rapidly, thus sustaining the ligand-specific conformation
longer. In the agonist-bound state, this would allow the receptor to amplify the signal by
prolonged G protein activation. Unlike rhodopsin, the activation in most other GPCRs
may require different dynamic parts of the receptor to achieve a sharp transition to active
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state. In this way, the ‘lid’ may help to ensure that the strain energy gain by agonist
and/or antagonist binding is efficiently transformed into helix rearrangement. In other
words, the ‘lid’ allows the ligand to flip the GPCR switch more easily and perhaps faster,
as suggested by Bourne and Meng (2000).
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CHAPTER VIII
FUTURE WORK

8.1 Introduction
The results presented in this thesis have shown that binding of agonist and
antagonist in AT1R induces formation of a distinct lid structure in ECL2, which closely
interacts with the ligand. The specific conformations of the lid, particularly around the
highly conserved disulfide bond that links ECL2 to TM III, were different in the Ang IIbound and losartan-bound states. Are specific ECL2-lid conformations necessary for
receptor activation and inhibition? Could ECL2 form a lid without the agonist, during
constitutive activation of AT1R? How are the dynamics of ECL2 conformation affected
by gain-of-function mutations located on TM-domain and loss-of-function mutations in
the N-terminal tail and ECL3? Is the ECL2 conformation in mutant receptors similar to
that of the empty-state or the ligand-bound state?

Coordinated movement of different domains within a GPCR is critical for its
biological function, transduction of signal across the membrane. Binding of a molecule to
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the EC-domain initiates local conformational changes that involve several intermediate
tates of dynamic movements within the protein. These dynamic movements take place in
the nanosecond timescale, and lead to long-range rearrangements in the TM and
cytoplasmic domains of GPCRs. Conformational changes also occur in the reverse order.
For instance, G-protein binding to a GPCR initially changes the local conformation of the
cytoplasmic loops, which subsequently propagates to the TM helices and the extracellular
domains. Domain coupling has been shown to be critical for the biological activity of
many different protein families with signaling and structural functions such as enzymes
and receptors. However, the regulation of dynamic processes that facilitate domain
coupling in proteins are poorly understood.

The critical nature of domain coupling in transmembrane signaling by GPCRs is
well documented. GPCRs exist in equilibrium between active and inactive conformations
in the absence of any ligand. Different types of ligands stabilize distinct conformations.
The inactive state of the receptor is stabilized by constraining intramolecular interactions;
agonists release the constraints leading to coupling of the cytoplasmic domain to the Gprotein. Thus, agonist activation is associated with the initiation of the signal at the ligand
binding site and the transmission of the signal along the transmembrane helices. Ligand
induced rearrangement of helices consequently leads to structural changes on the
cytoplasmic domain. On the other hand, antagonists and inverse agonists stabilize a more
constrained inactive conformation that decreases the affinity towards the G-protein.
Ligand-free GPCRs can also be driven to a high affinity state upon binding of G-protein
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to the cytoplasmic face of the receptor which suggests that the conformational changes in
the cytoplasmic domain are coupled to the conformation of the agonist binding site
(Karnik et al, 2003).

Gain-of-function, loss-of-function and misfolding mutants of GPCRs directly
alter domain coupling between the extracellular, transmembrane and cytoplasmic
domains of GPCRs (Karnik et al, 2003). Mutations that constitutively activate and
increase the G-protein coupling efficiency of GPCRs also increases the affinity towards
agonist by leading to a favorable reconfiguration at the agonist-binding site made up of
extracellular and transmembrane domain residues. In contrast, mutations that impair
agonist binding disrupt favorable interactions between the agonist and the binding pocket,
thus keeping the cytoplasmic domain in a low-affinity state towards G-proteins. These
observations suggest that a mutation in a particular domain of the receptor causes a local
structural perturbation that can be transmitted to other domains leading to a global
consequence in terms of affinity towards ligands and G-protein.

Misfolding mutations of rhodopsin, known as retinitis pigmentosa (RP)
mutations, have been extensively studied. These studies suggested that the cooperativity
between different domains originated from the tertiary folding of the receptor
polypeptide. (Spiegel, 1996, Berson, 1996, Hwa et al, 1997) RP mutations can also be
located in the extracellular, transmembrane and cytoplasmic domains of rhodopsin and
results in partially or completely misfolded receptors, suggesting that the coupling of
tertiary structures of different domains take place during folding of the receptor
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polypeptide. The misfolding of the receptor due to a RP mutation is usually associated
with the loss of formation of the disulfide bond between TMIII and ECL3 of rhodopsin,
which is conserved in more than 90% of GPCRs (Hwa et al, 1999 & 2001). This disulfide
bond in rhodopsin is critical for generating the functionally active structure of the
rhodopsin (Karnik et al, 1988).

We propose that domain coupling is a central phenomenon of the GPCRs
including AT1R (Karnik et al, 2003). The major structural evidence of domain coupling
in GPCRs is the interhelical contacts in the TM domain. Intramolecular contacts,
hydrophobic interactions and salt bridges between the extracellular domain and the TM
domain indicate that the activity of TM domain is regulated by the structural features of
the extracellular domain in GPCRs.

Very little is known about the ligand-specific conformational changes in the
extracellular domain and coupling of these movements to the TM domain. The results of
this thesis project provide evidence for conformational coupling between the ECL2 and
the ligand binding site, showing that different molecules targeting this region stabilize
distinct conformations that would eventually affect the transmembrane and cytoplasmic
domain conformation. In the AT1R model, ECL2 has been shown to have extensive
contacts with the N-terminal tail, ECL3 and TM helices. (Fig. 8.1) Therefore we propose
that the ECL2 conformation is influenced by mutations in the N-terminal tail, ECL3 and
TM domain. Several residues on the N-terminal tail, ECL3 and TM domain of AT1R
have been found to be important for both ligand binding and activation of the receptor.
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What is the effect of specific residue mutations in these domains on the conformation of
ECL2 in the absence and presence of different types of ligands?

8.2 Experimental Design
In order to determine the effects of structural changes in the other domains of the
receptor on the ECL2 conformation, we will utilize the gain-of-function and the loss-offunction mutants of AT1R. The conformational effects of these substitutions on the ECL2
will be analyzed by measuring the accessibility of selected ECL2 residues in the presence
of activating or inactivating substitutions, using the reporter cysteine accessibility
mapping analysis with the same approach applied before.

First, we want to analyze the effect of a gain-of-function substitution of Asn111
residue, found on TMIII with glycine (Fig. 8.2). Asn111 residue interacts with the Tyr4 of
Ang II (Feng et al, 1998) and is positioned close to the highly conserved disulfide bond
that links TMIII to ECL2. Asn111 to Gly111 substitution leads to a constitutively active
AT1R. The N111G-AT1R has been shown to have 50% more activity compared to wild
type receptor (Feng et al, 1998). As the size of the substituted residue decreases, the basal
IP3 production increases (Fig. 8.3). The N111G-AT1R showed higher affinity for Ang II
and lower affinity for losartan (Fig. 8.3). Since N111G-AT1R mutants is constitutively
activated, it is assumed to be in an active conformation. Is the conformation of ECL2 in
N111G-CYS¯AT1R similar to that of the Ang II-bound state of CYS¯AT1R?
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Figure 8.1. ECL2 interactions with NT, ECL3 and TM helices. A) Predicted
interactions of NT (purple) with ECL1 (blue), ECL2 (green) and ECL (red). B) Predicted
interaction of ECL2 (green) with ECL1 (blue) and ECL3 (red). C) Predicted interaction
of ECL2 (green) with TM helices: TMI (purple), TMII (purple), TMIII (red), TMVII
(blue). (Courtesy of Camelia Gogonea and S.Karnik)
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Figure 8.2. The positions of substitutions to be analyzed. The substitutions selected to
analyze are Arg23 on N-terminal tail, Asn111 on TMIII and Asp281 on ECL3, shown in red
circles. These substitutions are combined with ECL2 reporter cysteines replacing Asn174,
Asn176, Phe182 and Arg187, shown in pink circles. Cysteine residues substituted with
alanine are shown in green circles. Cysteine residues involved in formation of disulfide
bonds are shown in gold circles.
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Figure 8.3. Characteristics of N111G-AT1R. A) IP production without agonist
activation is measured as the percentage of IP produced by the same receptor when
stimulated with 1 µM [Sar1] Ang II (100%) in parallel. Details are given by Miura et al,
2002. B) The affinities of wild type AT1R and N111G-AT1R for Ang II and losartan.
Details are given by Feng et al, 1998.
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The other substitution that will be analyzed for its effects on ECL2 conformation
is Arg23 to alanine substitution. Arg23 is located on the N-terminus of AT1R (Fig. 8.2). It
interacts with Asp1 of Ang II. Its interaction with Asn176 of ECL2 has also been predicted
(Gogonea & Karnik, 2006). The R23A-AT1R has been shown to have a reduced efficacy
for Ang II (Santos et al, 2004). On the other hand it has a similar efficacy for losartan
compared to wild type AT1R indicating that the mutation does not cause a gross defect in
the receptor structure. Similarly, substitution of Asp281 to alanine also reduces the
efficacy of the receptor towards Ang II, without changing the efficacy towards losartan
(Hjorth et al, 1994, Feng et al, 1995, Costa-Neto et al, 2000, Santos et al, 2004). Asp281
residue is located on the ECL3 and interacts with the Arg2 of Ang II (Fig. 8.2). Its
interaction with Asn174 of ECL2 is also predicted (Gogonea & Karnik, 2006). Since these
two substitutions result in loss-of-function mutants, they are assumed to be in a
conformation that disfavors efficient binding of Ang II and accounts for a low-affinity
state. Is the conformation of ECL2 in R23A-CYS¯AT1R and D281A-CYS¯AT1R
similar to that of empty state or losartan-bound state of CYS¯AT1R?

In order to determine the conformational effects of these substitutions on the
ECL2, we will measure the accessibility of reporter cysteines replacing selected ECL2
residues generated on the background of N111G-CYS¯AT1R, R23A-CYS¯AT1R and
D281A-CYS¯AT1R. The selected ECL2 single cysteine mutants are N174C, N176C,
F182C and R187C. These residues are shown to be highly sensitive to changes in the
conformational state of the receptor based on our previously generated accessibility
maps. The reasons for choosing these ECL2 residues for this analysis are listed below.
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N174C:
● close to Ile172 which is crosslinked to AngII
● accessible in the absence of ligand and inaccessible in the presence of both AngII and
losartan
● in the autoantibody binding region

N176C:
● inaccessible in the absence of ligand, accessible in the presence of losartan
● close to the disulfide bond
● in the autoantibody binding region

F182C:
● inaccessible in the absence of ligand, accessible in the presence of AngII
● close to the disulfide bond
● in the autoantibody binding region

R187C:
● accessible in the absence of ligand, inaccessible in the presence of both AngII and
losartan
● in the autoantibody binding region

The NIIIG mutation, R23A mutation and D281A mutation were simultaneously
introduced into these single cysteine mutants by PCR mutagenesis as described in Figure
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2.4. NIIIG-CYS¯AT1R mutant, R23A-CYS¯AT1R mutant and D281A-CYS¯AT1R
mutant were also created for use as a control. The list of primers used in the PCR
mutagenesis is provided in the Table VIII.I. The double mutants constructed for MTSEAbiotin accessibility are listed in the Table VIII.II. All receptor mutants were confirmed by
automated sequencing.

Following construction of mutants, we started characterization of mutants. The
expression analysis of N111G single cysteine mutants was performed by western blotting
(Fig. 8.4). The expression patterns of all mutants were similar to HA-CYS¯AT1R,
although there is a decrease in the expression. Further we analyzed the cell surface
expression and binding affinities of N111G mutants by calculating Kd and Bmax values
from scathchard plots (Table VIII.III). As expected we observed a higher affinity for
[127I]-[Sar1Ile8] Ang II with the N111G single cysteine mutants compared to HACYS¯AT1R. We also calculated the number of receptors on the cell surface to make sure
that we have enough number of receptors on the cell surface especially for mutants with
low Bmax values to perform accessibility analysis. The characterization of R23A and
D281A mutants will be completed in the same way. The mutants will also be analyzed
for their abilities to activate Ang II induced signaling pathway by Ca2+ transient
measurements. After completion of characterization of mutants, we will determine the
accessibility of mutants using the RCAM analysis with the same approach applied before
in order to determine the conformational effects of these substitutions on the ECL2.
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Table VIII.I. The list of primers used to generate N111G, R23A and D281A
substitutions.
PRIMER

SEQUENCE

bp

%GC TM

N111G sense

GCCAGCGTGAGCTTCGGCCTCTACGCG

27

70.38

102.06

N111G antisense

CGCGTAGAGGCCGAAGCTCACGCTGGC

27

70.38

102.06

R23A sense

CCGAAGGCTGGAGCTCACAGTTAC

24

58.34

89.09

R23A antisense

GTAACTGTGAGCTCCAGCCTTCGG

24

58.34

89.09

D281A sense

GACATCGTGGCCACTGCCATGCCC

24

66.67

98.76

D281A antisense

GGGCATGGCAGTGGCCACGATGTC

24

66.67

98.76
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Table VIII.II. List of double mutants. N111G-CYS¯AT1R, R23A-CYS¯AT1R and
D281A-CYS¯AT1R are generated using HA-CYS¯AT1R background. The respective
single cysteine mutants of ECL2 (available from the previous study) were used as
templates to incorporate N111G, R23A and D281A substitutions simultaneously. All
mutants have the HA epitope to facilitate analysis.

N111G single cysteine mutants

R23A single cysteine mutants

D281A single cysteine mutants

N111G-CYS¯AT1R

R23A-CYS¯AT1R

D281A-CYS¯AT1R

N111G-N174C-CYS¯AT1R

R23A-N174C-CYS¯AT1R

D281A-N174C-CYS¯AT1R

N111G-N176C-CYS¯AT1R

R23A-N176C-CYS¯AT1R

D281A-N176C-CYS¯AT1R

N111G-F182C-CYS¯AT1R

R23A-F182C-CYS¯AT1R

D281A-F182C-CYS¯AT1R

N111G-R187C-CYS¯AT1R

R23A-R187C-CYS¯AT1R

D281A-R187C-CYS¯AT1R

155

Figure 8.4. Expression of ECL2 single cysteine mutants with N111G mutation.
Expression analysis of HA-CYS¯AT1R (lane 2) and HA-tagged single cysteine mutants
with N111G substitution (lanes 3-7) in transiently transfected COS1 cells. Untransfected
cells served as negative control (lane 1). Actin expression levels are shown as loading
control.
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Table VIII.III. Binding analysis of ECL2 single cysteine mutants with N111G
mutation. The Kd value of HA-CYS¯AT1R was 5.10 nm and Bmax value was 7.46
pmol/mg in the same experiment (n=3). *Number of receptors on the cell surface calculated
by the formula: [(Bmax*Avogadro’s number) / number of cells].

Mutant

Kd (nm) ± S.E.M

Bmax (pmol/mg) ± S.E.M

~Molecules/cell*

N111G-CYS¯AT1R

1.21 ± 0.43

2.76 ± 0.63

166,211

N111G-N174C

3.43 ± 0.20

0.78 ± 0.15

46,972

N111G-N176C

1.15 ± 0.49

0.03 ± 0.01

1,806

N111G-F182C

2.47 ± 0.38

0.39 ± 0.14

23,486

N111G-R187C

2.45 ± 0.37

0.79 ± 0.12

47,574
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